U.S. patent application number 16/912886 was filed with the patent office on 2021-01-14 for hiv binding agents.
This patent application is currently assigned to Centre Hospitalier Universitaire Vaudois. The applicant listed for this patent is Centre Hospitalier Universitaire Vaudois, Institute for Research in Biomedicine. Invention is credited to Antonio Lanzavecchia, Giuseppe Pantaleo.
Application Number | 20210009661 16/912886 |
Document ID | / |
Family ID | 1000005109494 |
Filed Date | 2021-01-14 |
![](/patent/app/20210009661/US20210009661A1-20210114-D00000.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00001.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00002.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00003.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00004.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00005.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00006.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00007.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00008.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00009.png)
![](/patent/app/20210009661/US20210009661A1-20210114-D00010.png)
View All Diagrams
United States Patent
Application |
20210009661 |
Kind Code |
A1 |
Pantaleo; Giuseppe ; et
al. |
January 14, 2021 |
HIV Binding Agents
Abstract
This disclosure relates to binding agents with specificity for
HIV and to methods for using the same to treat, pre-vent and/or
ameliorate HIV infection and/or AIDS.
Inventors: |
Pantaleo; Giuseppe;
(Lausanne, CH) ; Lanzavecchia; Antonio; (Via
Vincenzo Vela, CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Centre Hospitalier Universitaire Vaudois
Institute for Research in Biomedicine |
Lausanne
Bellinoza |
|
CH
CH |
|
|
Assignee: |
Centre Hospitalier Universitaire
Vaudois
Lausanne
CH
Institute for Research in Biomedicine
Bellinoza
CH
|
Family ID: |
1000005109494 |
Appl. No.: |
16/912886 |
Filed: |
June 26, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15780821 |
Jun 1, 2018 |
10730933 |
|
|
PCT/IB2016/057367 |
Dec 5, 2016 |
|
|
|
16912886 |
|
|
|
|
62263618 |
Dec 5, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/52 20130101;
C07K 2317/565 20130101; C07K 2317/76 20130101; C07K 2317/92
20130101; C07K 16/1063 20130101; C07K 2317/21 20130101 |
International
Class: |
C07K 16/10 20060101
C07K016/10 |
Claims
1. A binding agent that neutralizes HIV in an in vitro HIV
neutralization assay and/or in vivo, the binding agent at least one
amino acid sequence selected from the group consisting of SEQ ID
NOS. 1-32 and/or shown in Table 1.
2-17. cancelled
18. The binding agent of claim 1 comprising a conservative
substitution of an amino acid residue of any one or more of SEQ ID
NOS. 1-32.
19. The binding agent of claim 1 derived from a human antibody,
human IgG, human IgG1, human IgG2, human IgG2a, human IgG2b, human
IgG3, human IgG4, human IgM, human IgA, human IgAl, human IgA2,
human IgD, human IgE, canine antibody, canine IgGA, canine IgGB,
canine IgGC, canine IgGD, chicken antibody, chicken IgA, chicken
IgD, chicken IgE, chicken IgG, chicken IgM, chicken IgY, goat
antibody, goat IgG, mouse antibody, mouse IgG, pig antibody, and
rat antibody.
20. A derivative of a binding agent of claim 1.
21. The derivative of claim 20 selected from the group consisting
of an F.sub.ab, F.sub.ab2, Fab' single chain antibody, F.sub.v,
single chain, mono-specific antibody, bispecific antibody, trimeric
antibody, multi-specific antibody, multivalent antibody, chimeric
antibody, canine-human chimeric antibody, canine-mouse chimeric
antibody, antibody comprising a canine Fc, humanized antibody,
human antibody, caninized antibody, CDR-grafted antibody, shark
antibody, nanobody, and canelid antibody.
22-26. canceled
27. An isolated polynucleotide encoding a binding agent of claim
1.
28. The isolated polynucleotide of claim 28 comprising a nucleic
acid sequence of at least one of SEQ ID NOS. 37-72.
29. An expression vector comprising one or more polynucleotides of
claim 27.
30. A host cell comprising the isolated polynucleotide of claim
27.
31. A composition comprising at least one binding agent of claim 1;
and, a pharmaceutically acceptable carrier.
32. A method for detecting HIV on a cell, the method comprising
contacting a test biological sample with a binding agent of claim 1
and detecting the binding agent bound to the biological sample or
components thereof.
33. The method of claim 32, further comprising comparing the amount
of binding to the test biological sample or components thereof to
the amount of binding to a control biological sample or components
thereof, wherein increased binding to the test biological sample or
components thereof relative to the control biological sample or
components thereof indicates the presence of a cell expressing HIV
in the test biological sample.
34. The method of claim 32 wherein the test biological sample is
mammalian blood, wherein the method is an in vivo method or an in
vitro method.
35. canceled
36. canceled
37. A method for treating, preventing and/or ameliorating HIV
infection and/or AIDS in a mammal comprising administering to the
mammal at least one effective dose of a pharmaceutical composition
comprising a binding agent of claim 1.
38. The method of claim 37 wherein multiple doses are administered
to the animal.
39. The method of claim 37 wherein the binding agent is
administered in a dosage amount of about 1 to 50 mg/kg.
40. A kit for detecting the expression of HIV in or on a cell, the
kit comprising a binding agent of claim 1 and instructions for
use.
41. The kit of claim 40 wherein the binding agent, antibody, or
derivative is in lyophilized form.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 15/780,821 filed on Jun. 1, 2018 which was filed under 35
U.S.C. .sctn. 371 from International Application No.
PCT/IB2016/057367 filed on Dec. 5, 2016, which claims priority to
U.S. application Ser. No. 62/263,618 filed on Dec. 5, 2015; each of
which being hereby incorporated by reference into this disclosure
in their entirety.
FIELD OF THE DISCLOSURE
[0002] This disclosure relates to binding agents with specificity
for human immunodeficiency virus (HIV), methods for making the
same, and to methods for using the same to treat and/or prevent HIV
infection.
Background of the Disclosure
[0003] As we enter the fourth decade of the HIV epidemic,
significant advances have been made in the understanding of HIV
pathogenesis and in the development of potent and safe antiviral
drugs. More than 30 antiviral drugs have been registered and the
impact of combination antiretroviral therapy (ART) on both
morbidity and mortality has been remarkable. However, despite the
long-term suppression of HIV replication achieved in patients with
optimal adherence to ART, HIV invariably rebounds after
interruption of therapy. Furthermore, successful therapy does not
induce or allow restoration/development of virus-specific immune
responses capable of controlling HIV replication in the absence of
ART. Thus, life-long ART is needed to control HIV replication and
associated disease in the large majority of HIV infected
subjects.
[0004] A number of immunological interventions have been
investigated in the past and currently being further developed with
the goal to achieve HIV functional cure, wherein viral replication
is suppressed without sustained antiviral therapy. Therapeutic
vaccine strategies have been the primary intervention strategy
investigated but the results have shown modest efficacy in
experimental animal models and patients with the exception of a
CMV-based vector HIV vaccine (50% efficacy in the NHP model).
Recent studies have generated interesting results on the
possibility of using anti-envelope broad neutralizing antibodies
(bNabs) as therapeutic agents in HIV infection.
[0005] There is a need in the art for additional reagents for
targeting HIV, especially neutralizing antibodies, and methods for
using the same. This disclosure addresses those needs by providing
reagents and methods that may be used to target HIV and cells
and/or tissues infected by and /or harboring the same.
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] In the following a brief description of the appended figures
will be given. The figures are intended to illustrate the present
invention in more detail. However, they are not intended to limit
the subject matter of the invention in any way.
[0007] FIG. 1 shows the results of neutralization of a panel of
nine (9) HIV-1 pseudoviruses from the Global Panel of HIV-1
reference strains by 70 plasma samples from chronically infected
patients naive to antiretroviral therapy. MLV pseudovirus is used
as a negative control. Boxed are the seven donors selected for the
collection of lymph nodes to isolate potent broadly neutralizing
antibodies. Highlighted with the arrow is donor SA003 who was
selected for the isolation of the broadly neutralizing antibody
described in the present invention. ID50 values indicate the
dilution of plasma capable of neutralizing 50% of viral infection.
FIG. 1A illustrates exemplary results. FIG. 1B illustrates
additional exemplary results. FIG. 1C illustrates additional
exemplary results. FIG. 1D illustrates additional exemplary
results.
[0008] FIG. 2 shows the gating and sorting strategy used to purify
memory and germinal center IgG B cells from lymph node samples. B
cells were selected for the expression of the surface marker CD19
and IgG B cells were negatively selected for the lack of IgA and
IgM B cell receptor (BCR) expression. Germinal center B cells were
further selected for the expression of the CD38 marker (that is
absent on memory B cells).
[0009] FIG. 3 shows the results of neutralization of a panel of
nine (9) HIV-1 pseudoviruses (and MLV as negative control) from the
Global Panel of HIV-1 reference strains by different concentration
(in .mu.g/ml) of the monoclonal antibody LN01. IC50 values indicate
the concentration of monoclonal antibody capable of neutralizing
50% of viral infection. Error bars indicate the standard deviation
of duplicates. FIG. 3A illustrates exemplary results regarding
BJOX, CE1176(C), TRO.11 (B), X1632 (G), and CH119 (CRF07_BC). FIG.
3B illustrates additional exemplary results regarding CNE55
(CRF01_AE), 25710 (C), 246F3 (AC), CE0217 (C), and SVA-MLV.
[0010] FIG. 4 shows the results of neutralization of a multi-clade
panel of 118 HIV-1 pseudoviruses by the monoclonal antibody LN01.
IC50 values indicate the concentration of monoclonal antibody
capable of neutralizing 50% of viral infection.
[0011] FIG. 5 shows the distribution of IC50 values on the whole
panel of 118 viruses described in FIG. 4 and on individual clades
or circulating recombinant forms. FIG. 5A illustrates exemplary
results regarding all viruses. FIG. 5B illustrates exemplary
results regarding clade A. FIG. 5C illustrates exemplary results
regarding clade B. FIG. 5D illustrates exemplary results regarding
clade C. FIG. 5E illustrates exemplary results regarding clade D.
FIG. 5F illustrates exemplary results regarding clade G. FIG. 5G
illustrates exemplary results regarding CRF01_AE. FIG. 5H
illustrates exemplary results regarding CRF02_AG. FIG. 51
illustrates exemplary results regarding CRF07_BC. FIG. 5J
illustrates exemplary results regarding clades CD, AC and ACD.
[0012] FIG. 6 shows the results of neutralization of a panel of
nine (9) HIV-1 pseudoviruses from the Global Panel of HIV-1
reference strains by the monoclonal antibody LN01 when using TZM-bl
or TZM-bl expressing Fc gamma Receptor I as target cells.
[0013] FIG. 7 shows the results of neutralization of a panel of
seven (7) HIV-2/HIV-1 chimeric pseudoviruses where the HIV-2
(strain 7312A) MPER region is mutagenized by introducing
corresponding residues from the MPER consensus sequence of clade B
or clade C (in the case of the variant 7312A.C1C) HIV-1
strains.
[0014] FIG. 8 shows the binding of LN01 or 7B2 monoclonal
antibodies to an array of 1423 15-mer peptides, overlapping by 12
amino acids, that cover the full length of the consensus HIV-1 Env
gp160 sequences for clades A, B, C, D, group M, CRF01_AE and
CRF02_AG. Signals below 2.0E+4 are scored as negative. As expected
7B2 reacts with the gp41 immunodominant region (gp41 ID). FIG. 8A
illustrates exemplary results regarding LN01 Binding to gp120
Consensus Sequences. FIG. 8B illustrates exemplary results
regarding 7B2 Binding to gp120 Consensus Sequences. FIG. 8C
illustrates exemplary results regarding LN01 Binding to gp41
Consensus Sequences. FIG. 8D illustrates exemplary results
regarding 7B2 Binding to gp41 Consensus Sequences.
[0015] FIG. 9 show the binding, as assessed by surface plasmon
resonance, of LN01, PGT145, PGT151 and 17B monoclonal antibodies to
the cleaved and soluble HIV-1 Env trimer BG505 SOSIP.664 gp140 that
expresses multiple epitopes for broadly neutralizing in the
presence or absence of soluble CD4 (sCD4). As expected PGT145
(V1-V2 glycan specific) and PGT151 (binding to a site at the
interface between gp120 and gp41) bound with high affinity to BG505
SOSIP.664 gp140 in the absence and presence of sCD4, while 17b
(binding to a CD4 binding induced site) bound only in the presence
of sCD4. FIG. 9A: LN01. FIG. 9B: PGT145. FIG. 9C: PGT151. FIG. 9D:
17B.
[0016] FIG. 10 show the binding, as measured by ELISA, of LN01 and
10E8 (MPER-specific broadly neutralizing antibody) antibodies to a
set of HIV-1 Env antigens and a negative control (Ctr) antigen.
10E8 antibody reacted to the recombinant ecto-domain of gp41 that
contains the MPER region. FIG. 10A: 10E8. FIG. 10B: LN01.
[0017] FIG. 11 shows the binding, as measured by ELISA, of LN01 and
10E8 monoclonal antibodies to a fusion intermediate gp41 (gp41int)
or uncoated plates as a negative control (PBS). 10E8 antibody
reacted to gp41 that contains the MPER region. FIG. 11A: LN01. FIG.
11B: 10E8.
[0018] FIG. 12 shows the binding of mAb 10E8 to the gp41 peptide
RRR-NEQELLELDKWASLWNWFDITNWLWYIRRRR (SEQ ID NO. 89).
[0019] FIG. 13 shows the potency of LN01 antibody point mutation
variants. FIG. 13A. LN01 VH and VL variants. FIG. 13B. IC.sub.50
(.mu.g/ml) of LN01 variants. FIG. 13C. IC.sub.50 ratio (IC.sub.50
LN01 wt/IC.sub.50 LN01 variants ("var.")).
[0020] FIG. 14 shows testing of LN01 variants 7, 8 and 38 in
parallel with the parental LN01 antibody against a multiclade panel
of eight viruses. FIG. 14A: Percent (%) neutralization (TRO.11).
FIG. 14B: Percent (%) neutralization (246F3). FIG. 14C. Percent (%)
neutralization (CH119). FIG. 14D: Percent (%) neutralization
(BJOX). FIG. 14E: Percent (%) neutralization (X1632). FIG. 14F:
Percent (%) neutralization (25710). FIG. 14G: Percent (%)
neutralization (CNE55). FIG. 14H: Percent (%) neutralization
(CD1176). FIG. 14I: Percent (%) neutralization (SVA-MLV). FIG. 14J.
IC.sub.50 (.mu.g/m1). FIG. 14K. IC.sub.50 ratio (IC.sub.50 LN01
wt/IC.sub.50 LN01 variants ("var.")).
[0021] FIG. 15 shows testing of LN01 variants 41, 42, 43, 44, 48
and 50 against a multiclade panel of seven viruses. FIG. 15A:
IC.sub.50 (.mu.g/m1). FIG. 15B: IC.sub.50 ratio (IC.sub.50 LN01
wt/IC.sub.50 LN01 variants ("var.")).
[0022] FIG. 16 shows testing of LN01 variant 49 against a panel of
seven viruses. FIG. 16A: IC.sub.50 (.mu.g/m1). FIG. 16B: IC.sub.50
ratio (IC.sub.50 LN01 wt/IC.sub.50 LN01 variants ("var.")).
[0023] FIG. 17 shows testing of LN01 variant 82 (IC.sub.50
(.mu.g/ml)).
Summary of the Disclosure
[0024] This disclosure relates to binding agents with specificity
for human immunodeficiency virus (HIV), methods for producing such
binding agents, as well as methods for using such binding agents to
treat, prevent and/or ameliorate HIV infection.
DETAILED DESCRIPTION
[0025] This disclosure relates to binding agents having binding
affinity for human immunodeficiency virus (HIV). In some
embodiments, the binding agent can bind HIV antigens on viral
particles per se or on the surface of cells in vitro and/or in
vivo. The binding agents may also bind isolated HIV antigens and/or
fragments and/or derivatives thereof, typically in vitro. Also
provided are methods for using such binding agents to diagnose,
treat, prevent and / or ameliorate one or more diseases associated
with HIV. For instance, the binding agents may be antibodies (e.g.,
monoclonal antibodies) that may react with and/or bind to the
epitopes of HIV or polypeptides thereof. The binding agents may be
useful for treating disease caused by HIV, such as Acquired Immune
Deficiency Syndrome (AIDS). In some embodiments, the binding agents
described herein may selectively target and/or eliminate HIV and/or
HIV-infected cells containing HIV (e.g., replication competent HIV)
and/or expressing proteins thereof. In some embodiments, such cells
may be reservoirs for replication competent HIV. In some
embodiments, binding agents having, for instance, different
specificities (e.g., recognizing different epitopes) may be
combined to HIV activity such as infection, replication and/or
spread to other cells. In some embodiments, the binding agents
described herein may also provide for the selective elimination
and/or suppression of HIV or HIV-expressing cells. In some
embodiments, the binding agents described herein may be used to
supress and/or eliminate HIV and/or HIV-expressing cells to treat,
for instance, HIV infection and/or AIDS. Other embodiments, uses
and the like are described below.
[0026] The binding agents may be antibodies such as monoclonal
antibodies. As shown in the examples herein, the techniques
discussed below have been used to identify a fully human mAb termed
"LN01", having particular characteristics that are described herein
and shown in the examples. The LN01 antibody was isolated and the
amino acid sequences of variable heavy (V.sub.H) and light
(V.sub.L) chain domains of said antibody determined. A binding
agent such as LN01 may identified by referencing the amino acid
and/or nucleic acid sequences corresponding to the variability
and/or complementarity determining regions ("CDRs") thereof. A CDR
comprises amino acid residues within the variable region identified
in accordance with the definitions of the Kabat, Chothia, the
accumulation of both Kabat and Chothia, AbM, contact, and/or
conformational definitions or any method of CDR determination well
known in the art. antibody modeling software (now Accelrys.RTM.),
or the "contact definition" of CDRs based on observed antigen
contacts described by MacCallum et al., 1996, J. Mol. Biol.,
262:732-745. In the "conformational definition" of CDRs, the
positions of the CDRs may be identified as the residues that make
enthalpic contributions to antigen binding (Makabe et al., 2008,
Journal of Biological Chemistry, 283:1156-1166). Still other CDR
boundary definitions may not strictly follow one of the above
approaches, but may nonetheless overlap with at least a portion of
the Kabat CDRs, although they may be shortened or lengthened in
light of prediction or experimental findings that particular
residues or groups of residues or even entire CDRs do not
significantly impact antigen binding. As used herein, a CDR may
refer to CDRs defined by any approach known in the art, including
combinations of approaches. The methods used herein may utilize
CDRs defined according to any of these approaches. For any given
embodiment containing more than one CDR, the CDRs may be defined in
accordance with any of Kabat, Chothia, extended, AbM, contact,
and/or conformational definitions.
[0027] The amino acid sequences of the heavy chain CDRs (CDRH1,
CDRH2, CDRH3), light chain CDRs (CDRL1, CDRL2 (and CDRL2 long),
CDRL3), V.sub.H and V.sub.L domains of LN01 and certain exemplary
variants thereof are shown in Table 1 below.
TABLE-US-00001 TABLE 1 SEQ ID Amino Acid Sequence LN01 region NO.
(one letter code) LN01 CDRH1 1 GDSVSNDNYY LN01 CDRH2 2 IYYSGTT LN01
CDRH3 3 VRMPSHGFWSTSFSYWYFDL LN01 CDRL1 4 QSVTKY LN01 CDRL2 -- GTY
LN01 CDRL2 (long) 5 LIYGTYTLL LN01 CDRL3 6 QQAHSTPWT LN01 Variable
Heavy 7 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNDN (V.sub.H) (CDRH1,
YYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRN CDRH2 and CDRH3
RVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMP underlined)
SHGFWSTSFSYWYFDLWGRGHFVAVSW LN01 Variable Light 8
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN (V.sub.L) (CDRL1, CDRL2
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG and CDRL3
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT underlined) HVAAN LN01 variant 7
9 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNW Variable Heavy (V.sub.H)
NYYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLR (CDRH1, CDRH2
NRVTISLDKSVNVVSLRLGSVSAADTAQYYCVRM and CDRH3
PSHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 7 10
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (V.sub.L)
WYQFKTGQAPRILIYGTYFTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 8 11 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSND Variable Heavy
(V.sub.H) WYYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLR (CDRH1, CDRH2
NRVTISLDKSVNVVSLRLGSVSAADTAQYYCVRM and CDRH3
PSHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 8 12
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (V.sub.L)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 38 13 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNDN Variable Heavy
(V.sub.H) YYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRN (CDRH1, CDRH2
RVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMP and CDRH3
SHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 38 14
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (V.sub.L)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGWG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 41 15 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNFN Variable Heavy
(V.sub.H) YYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRN (CDRH1, CDRH2
RVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMP and CDRH3
SHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 41 16
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (V.sub.L)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 42 17 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNYN Variable Heavy
(V.sub.H) YYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRN (CDRH1, CDRH2
RVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMP and CDRH3
SHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 42 18
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (VL)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 48 19 QLQLQESGPGLVKPSETLSLTCTVSGDSVSNWN Variable Heavy
(V.sub.H) YYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRN (CDRH1, CDRH2
RVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMP and CDRH3
SHGFWSTSFSYWYFDLWGRGTLVTVSS underlined) LN01 variant 48 20
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (Vl)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 49 21 EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNW Variable Heavy
(V.sub.H) WYYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLR (CDRH1, CDRH2
NRVTISLDKSVNVVSLRLGSVSAADTAQYYCVRM and CDRH3
PSHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 49 22
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (VL)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variant 82 23 QVQLEESGPGLVQPWGTLSLTCRVSGGSISSSS Variable Heavy
(V.sub.H) YYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRN (CDRH1, CDRH2
RVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMP and CDRH3
SHGFWSTSFSYWYFDLWGRGHFVAVSW underlined) LN01 variant 82 24
DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLN Variable Light (VL)
WYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSG (CDRL1, CDRL2 and
SLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGT CDRL3 underlined) HVAAN LN01
variants 7 and 25 GDSVSNWNYY 48 Variable Heavy (V.sub.H) CDRH1 LN01
variant 8 26 GDSVSNDWYY Variable Heavy (V.sub.H) CDRH1 LN01 variant
41 27 GDSVSNFNYY Variable Heavy (V.sub.H) CDRH1 LN01 variant 42 28
GDSVSNYNYY Variable Heavy (V.sub.H) CDRH1 LN01 variant 43 29
GDSVSNLNYY Variable Heavy (V.sub.H) CDRH1 LN01 variant 44 30
GDSVSNINYY Variable Heavy (V.sub.H) CDRH1 LN01 variant 49 31
GDSVSNWWYY Variable Heavy (V.sub.H) CDRH1 LN01 variant 82 32
GSISSSSYY Variable Heavy (V.sub.H) CDRH1
[0028] A binding agent of this disclosure may comprise, for
example, any one or more of the amino acid sequences shown in Table
1 (i.e., any one or more of SEQ ID NOS. 1-32 or GTY (LN01 CDRL2)).
Fragments and/or derivatives (e.g., comprising substituted amino
acids, such as conservative substitutions) thereof are also
disclosed. An exemplary derivative of the LN01 antibody (an IgG3
antibody), for instance, is termed "IgG1 LN01" in which the LN01
variable regions were cloned into an IgG1 backbone. In some
embodiments, then, a binding agent of this disclosure may comprise
one or more (i.e., one, two, three, four, five, six or seven) of
SEQ ID NOS. 1-32. In some embodiments, it is preferred that the
binding agent comprise each of SEQ ID NOS. 1-6 and or GTY (LN01
CDRL2). In some embodiments, such a binding agent may comprise SEQ
ID NO. 7 and/or SEQ ID NO. 8; SEQ NOS. 9 and/or 10; SEQ NOS. 11
and/or 12; SEQ NOS. 13 and/or 14; SEQ NOS. 15 and/or 16; SEQ NOS.
17 and/or 18; SEQ NOS. 19 and/or 20; SEQ NOS. 21 and/or 22; or SEQ
NOS. 23 and/or 24; or a conservatively substituted variant thereof.
In preferred embodiments, the binding agent comprises SEQ ID NO. 7
and SEQ ID NO. 8; SEQ NOS. 9 and 10; SEQ NOS. 11 and 12; SEQ NOS.
13 and 14; SEQ NOS. 15 and 16; SEQ NOS. 17 and 18; SEQ NOS. 19 and
20; SEQ NOS. 21 and 22; or SEQ NOS. 23 and 24; or a conservatively
substituted variant thereof. In some embodiments, the binding agent
may comprise any of SEQ ID NOS. 1-32 comprising one or more amino
acid substitutions, in particular conservative substitutions (see,
e.g., Table 2). Exemplary variants of SEQ ID NO.:1 (LN01 CDR H1)
include, for instance, any of SEQ ID NOS. 25-32. In some
embodiments, the binding agent may be a monoclonal antibody or a
fragment or derivative thereof. In some embodiments, the binding
agent may be an HIV-binding fragment of such a monoclonal antibody.
Such embodiments would typically include at least one or more of
SEQ ID NOS. 1-32, and preferably include each of SEQ ID NOS. 1-6
(or GTY (LN01 CDRL2) such as SEQ ID NOS. 7-8; SEQ ID NO. 25 (LN01
variants 7 and 48 CDR H1); SEQ ID NO. 26 (LN01 variant 8 CDR H1);
SEQ ID NO. 27 (LN01 variant 41 CDR H1); SEQ ID NO. 28 (LN01 variant
42 CDR H1); SEQ ID NO. 29 (LN01 variant 43 CDR H1); SEQ ID NO. 30
(LN01 variant 44 CDR H1); SEQ ID NO. 31 (LN01 variant 49, a
combination of LN01 variant 7 CDR H1 and LN01 variant 8 CDR H1); or
SEQ ID NO. 32 (LN01 variant 82 CDR H1). In some embodiments, it may
be beneficial to avoid variants comprising a variable heavy chain
region comprising SEQ ID NO. 70 or 71 (LN01 variants 13 and 14,
respectively); tryptophan (W) at an amino acid corresponding to
amino acid 22 of SEQ ID NO. 70 (LN01 variant 13); tryptophan (W) at
an amino acid corresponding to amino acid 23 of SEQ ID NO. 71 (LN01
variant 14); a CDRH3 amino acid sequence of any of SEQ ID NOS.
72-78 (LN01 variants 18-24, respectively); alanine (A) at an amino
acid corresponding to amino acid 8 of SEQ ID NO. 72 (LN01 variant
18); alanine (A) at an amino acid corresponding to amino acid 9 of
SEQ ID NO. 73 (LN01 variant 19); tryptophan (W) at an amino acid
corresponding to amino acid 10 of SEQ ID NO. 74 (LN01 variant 20);
tryptophan (W) at an amino acid corresponding to amino acid 11 of
SEQ ID NO. 75 (LN01 variant 21); tryptophan (W) at an amino acid
corresponding to amino acid 12 of SEQ ID NO. 76 (LN01 variant 22);
tryptophan (W) at an amino acid corresponding to amino acid 14 of
SEQ ID NO. 77 (LN01 variant 23); tryptophan (W) at an amino acid
corresponding to amino acid 15 of SEQ ID NO. 78 (LN01 variant 24);
a variable light chain region comprising SEQ ID NO. 79 or 80 (LN01
variants 32 and 33, respectively); tryptophan (W) at an amino acid
corresponding to amino acid 5 of SEQ ID NO. 79 (LN01 variant 32);
and/or, tryptophan (W) at an amino acid corresponding to amino acid
6 of SEQ ID NO. 80 (LN01 variant 33), as these may not provide
suitable HIV neutralizing activity. Thus, in some embodiments, the
binding agent may comprise any of SEQ ID NOS. 1-32 but not those of
any one or more of SEQ ID NOS. 70-80. Other suitable embodiments
may be derived by those of ordinary skill in the art from this
disclosure.
[0029] It is preferred that the binding agent (e.g., antibody, or
the antigen binding fragment thereof), comprises one or more amino
acid sequences having at least 70%, at least 75%, at least 80%, at
least 85%, at least 88%, at least 90%, at least 92%, at least 95%,
at least 96%, at least 97%, at least 98% or at least 99% identity
to at least one of SEQ ID NOS. 1-32 (i.e., the CDR sequences, the
VH sequence and/or the VL sequence shown in Table 1). In some
embodiments, that percent identity is with respect to an amino acid
sequence of at least three amino acids (e.g., as in GTY of LN01
CDRL2), six amino acids (e.g., as in LN01 CDRL1 (SEQ ID NO.:4)),
seven amino acids (e.g., as in LN01 CDRH2 (SEQ ID NO.:2)), nine
amino acids (e.g., as in LN01 CDRL2 (long), (SEQ ID NO.:5), LN01
CDRL3 (SEQ ID NO.:6), LN01 variant 82 CDRH1 (SEQ ID NO. 32)), ten
amino acids (e.g., as in LN01 CDRH1 (SEQ ID NO.:1) or any of SEQ ID
NOS. 25-31), or twenty amino acids (e.g., as in LN01 CDRH3 (SEQ ID
NO.:3). As discussed below, identities of less than 100% may result
from the natural or synthetic substitution of one or more amino
acids with another amino acid(s), as in a conservative substitution
(see, e.g., Table 2). Various combinations of SEQ ID NOS. 1-32 may
be useful as may ascertained by one of ordinary skill in the art
using the techniques described herein or as may be otherwise
available to those of ordinary skill in the art. In preferred
embodiments, the binding agent binds HIV and/or cells infected by
HIV and/or expressing HIV proteins. In some especially preferred
embodiments, the binding agent neutralizes HIV as described herein.
In preferred embodiments, the binding agent both binds HIV and/or
cells infected by HIV and/or expressing HIV proteins, and
neutralizes HIV.
[0030] The variable region and/or CDR sequences (e.g., of Table 1)
may be used in combination with one or more other variable
region/CDR amino acid sequences available to those of ordinary
skill in the art. Such variable region/CDR amino acid sequences may
alternatively and/or also be adjoined to one or more types of
constant region polypeptides of an antibody molecule. For instance,
the CDR amino acid sequences shown in Table 1 may be adjoined to or
associated with the constant regions of any antibody molecule of
the same or a different species (e.g., human, goat, rat, sheep,
chicken) and/or antibody subtype of that from which the CDR amino
acid sequence was derived. For instance, an exemplary binding agent
may be, or may be derived from, one having about the same
neutralizing activity and/or binding the same or similar epitopes
and/or exhibiting about the same affinity as another binding agent
comprising one or more of the amino acid sequences shown in Table 1
(e.g., LN01 and IgG1 LN01). The binding agent may comprise an
antibody heavy and/or a light chain that each comprises one or more
constant and/or variable regions. Any of the amino acid sequences
described herein (e.g, as in Table 1), and/or any fragments and/or
derivatives thereof, may also be combined with any other variable
region and/or CDR in any order and/or combination to form new
binding agents, e.g., hybrid and/or fusion binding agents, and/or
inserted into other heavy and/or light chain variable regions using
standard techniques.
[0031] This disclosure also provides for the use of such binding
agents to isolate, identify, and/or target HIV and/or cells
harboring and/or infected by HIV and/or expressing HIV antigens. In
certain embodiments, such binding agents may be reactive against
HIV antigens such as proteins expressed on the surface of cells. In
some embodiments, the binding agent(s) is an antibody (antibodies).
The term "antibody" or "antibodies" may refer to whole or
fragmented antibodies in unpurified or partially purified form
(e.g., hybridoma supernatant, ascites, polyclonal antisera) or in
purified form. The antibodies may be of any suitable origin or form
including, for example, murine (e.g., produced by murine hybridoma
cells), or expressed as humanized antibodies, chimeric antibodies,
human antibodies, and the like. For instance, antibodies may be
wholly or partially dervied from human (e.g., IgG (IgG1, IgG2,
IgG2a, Ig2b, IgG3, IgG4), IgM, IgA (IgA1 and IgA2), IgD, and IgE),
canine (e.g., IgGA, IgGB, IgGC, IgGD), chicken (e.g., IgA, IgD,
IgE, IgG, IgM, IgY), goat (e.g., IgG), mouse (e.g., IgG, IgD, IgE,
IgG, IgM), pig (e.g., IgG, IgD, IgE, IgG, IgM), and/or rat (e.g.,
IgG, IgD, IgE, IgG, IgM) antibodies, for instance. Methods of
preparing, utilizing and storing various types of antibodies are
well-known to those of skill in the art and would be suitable in
practicing the present invention (see, for example, Harlow, et al.
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory,
1988; Harlow, et al. Using Antibodies: A Laboratory Manual,
Portable Protocol No. 1, 1998; Kohler and Milstein, Nature, 256:495
(1975)); Jones et al. Nature, 321:522-525 (1986); Riechmann et al.
Nature, 332:323-329 (1988); Presta (Curr. Op. Struct. Biol.,
2:593-596 (1992); Verhoeyen et al. (Science, 239:1534-1536 (1988);
Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J.
Mol. Biol., 222:581 (1991); Cole et al., Monoclonal Antibodies and
Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J.
Immunol., 147(1):86-95 (1991); Marks et al., Bio/Technology 10,
779-783 (1992); Lonberg et al., Nature 368 856-859 (1994);
Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature
Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology
14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93
(1995); as well as U.S. Pat. Nos. 4,816,567; 5,545,807; 5,545,806;
5,569,825; 5,625,126; 5,633,425; and, 5,661,016). In certain
applications, the antibodies may be contained within hybridoma
supernatant or ascites and utilized either directly as such or
following concentration using standard techniques. In other
applications, the antibodies may be further purified using, for
example, salt fractionation and ion exchange chromatography, or
affinity chromatography using Protein A, Protein G, Protein A/G,
and/or Protein L ligands covalently coupled to a solid support such
as agarose beads, or combinations of these techniques. The
antibodies may be stored in any suitable format, including as a
frozen preparation (e.g., -20.degree. C. or -70.degree. C.), in
lyophilized form, or under normal refrigeration conditions (e.g.,
4.degree. C.). When stored in liquid form, for instance, it is
preferred that a suitable buffer such as Tris-buffered saline (TBS)
or phosphate buffered saline (PBS) is utilized. In some
embodiments, the binding agent may be prepared as an injectable
preparation, such as in suspension in a non-toxic parenterally
acceptable diluent or solvent. Suitable vehicles and solvents that
may be utilized include water, Ringer's solution, and isotonic
sodium chloride solution, TBS and/or PBS, among others. Such
preparations may be suitable for use in vitro or in vivo may be
prepared as is known in the art and the exact preparation may
depend on the particular application.
[0032] The binding agents described herein are not, however, in any
way limited to antibodies (i.e., whole antibodies). For example,
the binding agent may be any compound exhibiting similar binding
properties as another (e.g., a mimetic). For example, an exemplary
binding agent may be one that binds HIV and/or can compete with
another binding agent having specificity therefor (e.g., a
monoclonal antibody such as LN01). In some embodiments, the mimetic
may exhibit substantially the same affinity in binding assays as
the binding agent (e.g., monoclonal antibody) to which it is being
compared. The affinity a particular binding agent may be measured
by any suitable assay including but not limited to FACS staining of
cell surface HIV antigens (e.g., polypeptides). One binding agent
may be said to have "substantially the same affinity" as another
where the measurements (e.g., nm) are within about any of
1-20,1-5,5-10,10-15, or 15-20 percent of one another. Exemplary
mimetics may include, for example, organic compounds that
specifically bind HIV, or an affibody (Nygren, et al. FEBS J. 275
(11): 2668-76 (2008)), affilin (Ebersbach, et al. J. Mol. Biol. 372
(1): 172-85 (2007)), affitin (Krehenbrink, et al. J. Mol. Biol. 383
(5): 1058-68 (2008)), anticalin (Skerra, A. FEBS J. 275 (11):
2677-83 (2008)), avimer (Silverman, et al. Nat. Biotechnol. 23
(12): 1556-61 (2005)), DARPin (Stumpp, et al. Drug Discov. Today 13
(15-16): 695-701 (2008)), Fynomer (Grabulovski, et al. J. Biol.
Chem. 282 (5): 3196-3204 (2007)), Kunitz domain peptide (Nixon, et
al. Curr. Opin. Drug Discov. Devel. 9 (2): 261-8 (2006)), and/or a
monobody (Koide, et al. Methods Mol. Biol. 352: 95-109 (2007)).
Other mimetics may include, for example, a derivative of an
antibody such as, for example, an F.sub.ab, F.sub.ab2, Fab' single
chain antibody, F.sub.v, single domain antibody, mono-specific
antibody, bi-specific antibody, tri-specific antibody, multi-valent
antibody, chimeric antibody, canine-human chimeric antibody,
canine-mouse chimeric antibody, antibody comprising a canine Fc,
humanized antibody, human antibody, caninized, CDR-grafted antibody
(i.e., comprising any of SEQ ID NOS. 1-32 shown in Table 1), shark
antibody, nanobody, canelid antibody, microbody, and/or intrabody,
or derivative thereof. Other binding agents are also provided
herein as would be understood by one of ordinary skill in the
art.
[0033] Any method known to those of ordinary skill in the art may
be used to generate binding agents having specificity for (e.g.,
binding to) HIV. For instance, to generate and isolate monoclonal
antibodies an animal such as a mouse may be administered (e.g.,
immunized) with one or more HIV proteins. Animals exhibiting serum
reactivity to HIV expressed on activated human T lymphocytes (as
determined by, for instance, flow cytometry and/or microscopy) may
then be selected for generation of anti-HIV hybridoma cell lines.
This may be repeated for multiple rounds. Screening may also
include, for instance, affinity binding and/or functional
characterization to identify the binding agent as an being specific
for HIV. In some embodiments, such as in the Examples herein, human
beings may be screened for the expression of antibodies against
HIV. In some embodiments, plasma samples of human beings infected
by HIV may be screened to identify persons expressing anti-HIV
antibodies, and in particular, neutralizing antibodies.
Neutralizing antibody-producing cells of such persons may then be
isolated, followed by the isolation and characterization of the
antibodies produced thereby (e.g., as in the examples herein). A
neutralizing antibody may be one that exhibits the ability to
neutralize, or inhibit, infection of cells by HIV. In general, a
neutralization assay typically measures the loss of infectivity of
the virus through reaction of the virus with specific antibodies.
Typically, a loss of infectivity is caused by interference by the
bound antibody with any of the virus replication steps including
but not limited to binding to target cells, entry, and/or viral
release. The presence of unneutralized virus is detected after a
predetermined amount of time, e.g., one, two, three, four, five,
six, seven, eight, nine, 10, 12 or 14 days, by measuring the
infection of target cells using any of the systems available to
those of ordinary skill in the art (e.g., a luciferase-based
system). A non-limiting example of a neutralization assay may
include combining a given amount of a virus or pseudovirus (see
below) and different concentrations of the test or control
(typically positive and negative controls assayed separately)
antibody or antibodies are mixed under appropriate conditions
(e.g., one (1) hour at room temperature) and then inoculated into
an appropriate target cell culture (e.g., TZM-bl cells). For
instance, binding agent-producing cells (e.g., B cells producing
antibodies) may be assayed for the production of HIV-1 neutralizing
antibodies by seeding such cells in separate plates as single cell
micro-cultures on human feeder cells in the presence of
Epstein-Barr Virus (EBV) (which also stimulate polyclonally memory
B cells), a cocktail of growth factors (e.g., TLR9 agonist
CpG-2006, IL-2 (1000 IU/ml), IL-6 (10 ng/ml), IL-21 (10 ng/ml), and
anti-B cell receptor (BCR) goat antibodies (which trigger BCRs).
After an appropriate time (e.g., 14 days), supernatants of such
cultures may tested in a primary luciferase-based screening system
using two or more representative HIV-1 viruses or pseudoviruses
that productively infect such cells. The pseudoviruses may be
incubated with B cell culture supernatants for an appropriate time
and temperature (e.g., one (1) h at 37% (5% CO.sub.2)) before the
addition of host cells (e.g., 3000 TZM-bl cells). Incubation for an
appropriate time (e.g., 72 hours) may then follow, after which the
supernatant may be removed and Steadylite reagent (Perkin Elmer)
added (e.g., 15 .mu.l). Luciferase activity may then deteremined
(e.g., five minutes later) on a Synergy microplate luminometer
(BioTek). Decreased luciferase activity relative to a negative
control typically indicates virus neutralization. Neutralization
assays such as these, suitable for analyzing binding agents of this
disclosure, are known in the art (see, e.g., Montefiori, D. C.
Curr. Protocol. Immunol. Chapter 12, Unit 12.11 (2005); Edmonds, et
al. Virology, 408(1): 1-13 (2010); Seaman, et al. J. Virol. 84(3):
1439-1452 (2010); Pace, et al. PNAS USA, 110(33): 13540-13545
(2013)). In some embodiments, test samples may be screened for the
presence of antibodies able to neutralize a panel of HIV
pseudoviruses (e.g., nine (9) HIV-1 pseudoviruses from the Global
Panel of HIV-1 reference strains as conducted in the examples
herein (those pseudoviruses being BJOX (CRF007_BC), CE1176 (C),
TRO.11 (B), X1632 (G), CH119 (CRF07_BC), CNE55 (CRF01_AE), 25710
(C), 246F3 (AC), CE0217 (C)); DeCamp, A. et al. Global panel of
HIV-1 Env reference strains for standardized assessments of
vaccine-elicited neutralizing antibodies. J Virol 88, 2489-2507
(2014)). Neutralization of a larger panel of psuedoviruses may also
be tested; for instance, de Camp et al. describe a group of 12
pseudoviruses (also known as HIV-1 Env Reference Strains): 398F1,
25710, CNE8, TRO11, X2278, BJOX2000, X1632, CE1176, 246F3, CH119,
CE0217, and CNE55. In some embodiments, a panel of ten HIV isolates
may be tested and a BNA may be identified as one that neutralizes
six, seven, eight, nine members of a panel of nine pseudoviruses;
or six, seven, eight, nine, 10, 11 or 12 members of a panel of 12
pseudoviruses. Screening of larger panels of such pseudoviruses
(e.g., a panel of 118 pseudoviruses as in the examples herein) may
also be carried out. An exemplary panel of 118 pseudoviruses used
in the examples against which test samples may be tested for
neutralizing antibodies may include, for instance, those shown in
FIG. 4 (including clade A, clade B, clade C, clade D, clade G,
circulating recombinant forms CRF10_CD, CRF10_AE, CRF02_AG and
CRF07_BC, as well as non-circulating recombinants AC and ACD
strains). In some embodiments, neutralization may be determined as
a measure of the concentration (e.g., .mu.g/ml) of monoclonal
antibody capable of neutralizing any of about 50%, 60%, 70%, 80%,
90%, 95%, or 99% of viral infection (an "IC.sub.50" value). In some
embodiments, a binding agent may be considered neutralizing if it
is able to neutralize 50% of viral infection at a concentration of,
for instance, about any of 10.sup.-5, 10.sup.-4, 10.sup.-3,
10.sup.-2, 10.sup.-1, 10.sup.0, 10.sup.1, 10.sup.2, or 10.sup.3
.mu.g/ml (an IC.sub.50 value as shown in in FIG. 3). In some
embodiments, as in the Examples herein, it is preferred that this
IC.sub.50 value be below 25 .mu.g/ml, and even more preferably
below about any of 15, 10, 5, 2, 1, 0.5, 0.25, 0.1, 0.05, or 0.01
.mu.g/ml. In preferred embodiments, as for the LN01 antibody
described herein, the IC.sub.50 value may be less than 0.011 (e.g.,
FIG. 7). In some embodiments, the ability of a neutralizing
antibody to neutralize viral infection may also be expressed as a
percent neutralization (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, 95%, or 99% (e.g., as in FIG. 3)). Other measures of
neutralization may also be suitable as may be determined by those
of ordinary skill in the art.
[0034] In some embodiments, the binding agents described herein may
be broadly neutralizing antibodies (BNAs) identified in biological
samples (e.g., plasma) obtained from HIV-infected persons. As
mentioned above and shown in the examples herein, such BNAs may be
identified by testing plasma samples of patients chronically
infected by HIV (preferably those naive to antiretroviral therapy)
for the ability to neutralize multi-clade HIV isolates (e.g.,
initially using a nine or 12-member panel and then a larger panel
(e.g., 118 members) of pseudoviruses)). In some embodiments, the
samples may be derived from patients known to be "Elite
Controllers" with viremia <50 HIV RNA copies per ml of plasma.
Screening procedures such as these may result in the identification
of patients that may serve as lymph node donors for the subsequent
isolation and characterization of B cells producing BNAs. In
carrying out such screening assays, neutralizing activity is
typically compared to a negative control such as murine leukemia
virus (MLV) pseudovirus.
[0035] In some embodiments, germinal center and memory IgG B cells
of patients expressing neutralizing binding agents (e.g.,
antibodies) may be isolated and further studied. In some
embodiments, the cells may be sorted separately according to IgG
(e.g., IgA and IgM negative cells), CD19, and CD38 expression
(germinal center B cells are CD38 positive) (see, e.g., FIG. 2) and
interrogated for the production of HIV-1 neutralizing antibodies.
For instance, highly pure IgG memory B cells and IgG germinal cells
may be seeded in separate plates as single cell micro-cultures on
human feeder cells in the presence of Epstein-Barr Virus (EBV)
(which also stimulate polyclonally memory B cells) and a cocktail
of growth factors and the like (e.g., composed TLR9 agonist
CpG-2006, IL-2 (1000 IU/m1), IL-6 (10 ng/ml), IL-21 (10 ng/ml), and
anti-BCR goat antibodies (B cell receptor (BCR) triggerring)).
Supernatants of such cultures (e.g., from day 14 cultures) may then
be tested in a primary screening (e.g., using a 384-well based
HIV-1 pseudoviruses neutralization assay using in parallel two
strains, CE1176 and BJOX2000, representative of clade C and CRF07,
as shown in the examples herein). Neutralization assays may be
carried out using any suitable host cells (e.g., TZM-bl cells
(Seaman, et al. J. Virol. 84(3): 1439-52 (2010); NIH AIDS Reagent
Program Catalog Number 8129)). HIV-1 pseudoviruses resulting in a
significant output relative light units (RLU) (e.g., of
50-100.times.10.sup.4 RLU) (i.e., indicating productive infection
of cells) may then incubated with B cell culture supernatants for
an appropriate time and temperature (e.g., one (1) h at 37% (5%
CO2)) before the addition of host cells (e.g., 3000 TZM-bl cells).
Incubation for an appropriate time (e.g., 72 hours) typically
follows, after which the supernatant may be removed and Steadylite
reagent (Perkin Elmer) added (e.g., 15 .mu.l). Luciferase activity
may then detected (e.g., five minutes later) on a Synergy
microplate luminometer (BioTek). Decreased luciferase activity
indicates a lesser amount of virus being released by the cells and
virus neutralization. For instance, if the base RLU for a
particular psuedovirus is 50-100.times.10.sup.4 RLU, a neutralizing
antibody may be determined to decrease the RLU for that pseudovirus
to 25-50.times.10.sup.4 RLU (i.e., a 50% decrease), or less. Using
such systems, supernatants capable of cross-neutralizing strains
may be identified, further harvested, and tested for their ability
to neutralize other pseudoviruses.
[0036] The antibodies derived from such neutralizing
antibody-containing cultures may then be further characterized by
determining the amino acid and nucleotide sequences of the antibody
variable and complementarity determining regions (CDRs) regions.
Using these techinques, the HIV-neutralizing binding agent termed
"LN01" was identified as an IgG3-type fully human monoclonal
antibody having the CDR, VH and VL sequences shown in Table 1 (SEQ
ID NOS. 1-7 and/or GTY). LN01 was determined to be derived from the
IGHV4-39*07 and IGKV1-39*01 germline genes and highly somatically
mutated in variable genes of both heavy chain (28%) and kappa light
chain (27%) compared to germ line. LN01 was also found to possess a
long heavy-chain complementarity-determining 3 region ("CDR H3")
loop composed of 20 amino acids. In some embodiments, the variable
heavy chain (V.sub.H) and variable light chain (V.sub.L) genes of a
binding agent may then be cloned into an IgG expression vector of
the same or a different isotype. As shown in the examples, for
instance, nucleic acids encoding LN01 CDRs (Table 3) were cloned
into IgG1 backbone, and the recombinant IgG1-based antibody (IgG1
LN01) was produced by transfecting appropriate host cells (e.g.,
Expi293F cells). The antibody full-length IgG1-based antibody may
then be purified using standard techniques (e.g., a full-length
IgG1-based antibody may be purified using a recombinant protein-A
column (GE-Healthcare)). The recombinantly-produced IgG1 antibody
may then be tested against any of a panel of pseudoviruses such as
any of those described herein (e.g., the Global Panel of nine (9)
HIV-1 reference pseudoviruses used in the examples) on an
appropriate host cell (e.g., TZM-bl cells). In preferred
embodiments, the binding agent will exhibit the ability to
neutralize a majority (i.e., at least about 50% or greater) of the
pseudovirus panel members (e.g., comprising nine, 12 or 118
members) without neutralizing a negative control virus (e.g., MLV
pseudovirus). It is preferred that the binding agent exhibit the
ability to neutralize a majority of such viruses (e.g.,
neutralization of greater than about 50%, such as any of about 60%,
70%, 80%, 90%, 95%, 99%, or 100%) with IC.sub.50 values considered
neutralizing (see below). For example, in some embodiments, a
binding agent of this disclosure may exhibit neutralization of
HIV-1 pseudoviruses BJOX (CRF07_BC), CE1176, TRO.11 (B), X1632 (G),
CH119 (CRF07_BC), CNE55 (CRF01_AE), 25710 (C), CD0217(C) but not of
the control virus SVA-MLV at about 10.sup.0 .mu.g/ml or less (FIG.
3). In some embodiments, neutralization of the HIV-1 pseudoviruses
viruses may be observed where the antibody concentration is from
10.sup.2-10.sup.0 .mu.g/ml, or between 10.sup.0-10.sup.1 .mu.g,/ml
(FIG. 3). In some such embodiments, the percent neutralization by
the binding agent is at least about 50% (FIG. 3). In some
embodiments, infection of one HIV-1 isolate is considered
neutralized by a binding agent (e.g., antibody) at an IC.sub.50 of
less than 25 .mu.g/ml, if infection of at least one isolate of this
isolate is neutralized with an IC.sub.50 of less than 25 .mu.g/ml.
In some embodiments, the binding agent may be considered
neutralizing where a majority of the 118 HIV-1 pseudoviruses listed
in FIG. 4 are considered neutralized at an IC.sub.50 of less than
25 .mu.g/ml, such as about 10 .mu.g/ml, 9 .mu.g/ml, 8 .mu.g/ml, 7
.mu.g/ml, 6 .mu.g/ml, 5 .mu.g/ml, 4 .mu.g/ml, 3 .mu.g/ml, 2
.mu.g/ml, 1 .mu.g/ml, 0.9 .mu.g/ml, 0.8 .mu.g/ml, 0.7 .mu.g/ml, 0.6
.mu.g/ml, 0.5 .mu.g/ml, 0.4 .mu.g/ml, 0.3 .mu.g/ml, 0.2 .mu.g/ml,
0.1 .mu.g/ml, 0.09 .mu.g/ml, 0.08 .mu.g/ml, 0.07 .mu.g/ml, 0.06
.mu.g/ml, 0.05 .mu.g/ml, 0.04 .mu.g/ml, 0.03 .mu.g/ml, 0.02
.mu.g/ml, or 0.01 .mu.g/ml. In preferred embodiments, the binding
agent may neutralize HIV-1 pseudovirus strains of ID 6535.3,
QH0692.42, SC422661.8, PVO.4, TRO.11, PEJ04541.67, WIT04160.33,
1006_11_C3_1601, 1054_07_TC4_1499, 1056_TA11_1826,
1012_11_TC21_3257, 6244_13_B5_4576, SC05_8C11_2344, Du156.12,
Du172.17, Du422.1, ZM197M.PB7, ZM214M.PL15, ZM233M.PB6, ZM249M.PL1,
ZM109F.PB4, ZM135M.PL10a, HIV-0013095-2.11, HIV-16055-2.3,
HIV-16845-2.22, Ce1086_B2, Ce1176_A3, Ce0682_E4, Ce1172_H1,
ZM247v1(Rev-), 3016.v5.c45, A07412M1.vrc12, 231966.c02, CNE20,
CNE21, CNE17, CNE30, CNE53, CNE58, 9004SS_A3_4, 928-28, 263-8,
T255-34, 211-9, 235-47, CNE8, C1080.c03, R2184.c04, R1166.c01,
C2101.c3347.c11, BJOX015000.11.5, BJOXX010000.06.2,
BJOX025000.01.1, BJOX028000.10.3, X1193_c1, X2131_C1_B5,
P1981_C5_3, 6952.v1.c20, and 0815.v3.c3 at an IC.sub.50 of less
than or about 1 .mu.g/ml (FIG. 4).
[0037] In some preferred embodiments, the binding agent may
neutralize HIV-1 pseudovirus strains of ID QH0692.42, SC422661.8,
PVO.4, TRO.11, PEJO4541.67, WITO4160.33, 1006_11_C3_1601,
1054_07_TC4_1499, 1056_TA11_1826, 6244_13_B5_4576, SC05_8011_2344,
Du156.12, Du172.17, ZM197M.PB7, HIV-0013095-2.11, HIV-16055-2.3,
HIV-16845-2.22, Ce1086_B2, Ce1172_H1, ZM247v1(Rev-), 3016.v5.c45,
A07412M1.vrc12, CNE20, CNE21, CNE53, CNE58, 9004SS_A3_4, 928-28,
263-8, T255-34, CNE8, C1080.c03, BJOX015000.11.5, BJOX010000.06.2,
BJOX025000.01.1, BJOX028000.10.3, X2131_C1_B5, P1981_C5_3,
6952.v1.c20, and 0815.v3.c3at an IC.sub.50 of less than or about
0.5 .mu.g/ml (FIG. 4). In some preferred embodiments, the binding
agent may neutralize HIV-1 pseudovirus strains of ID
1054_07_TC4_1499, 1056_TA11_1826, 6244_13_B5_4576, Du172.17,
HIV-0013095-2.11, HIV-16845-2.22, Ce1172_H1, CNE20, CNE21, 928-28,
CNE8, P1981_C5_3 at an IC50 of less than or about 0.1 .mu.g/ml
(FIG. 4). It is further preferred that the binding agent not
exhibit clade-dependency. For instance, in some embodiments, the
binding agent may exhibit the ability to neutralize pseudoviruses
of HIV-1 Clades B, B (T/F), C, C (T/F), D, D (T/F), BC, A, A (T/F),
CRF02_AG, CRF01_Ae, CRF01_AE (T/F), G, CD, AC and ACD (FIG. 4). In
some preferred embodiments, the binding agent may neutralize at
least one pseudovirus in each of clades B, B (T/F), C, C (T/F), D,
BC, A, A (T/F), CRF02_AG, CRF01_Ae, CRF01_AE (T/F), G, CD, and ACD
at at an IC.sub.50 of less than or about 1 .mu.g/ml (FIG. 4). In
some preferred embodiments, the binding agent may neutralize at
least one pseudovirus in each of clades B, B (T/F), C, C (T/F), D,
BC, A (T/F), CRF02_AG, CRF01_Ae, CRF01_AE (T/F), G, CD, and ACD at
at an IC.sub.50 of less than or about 0.5 .mu.g/ml (FIG. 4). In
some preferred embodiments, the binding agent may neutralize at
least one pseudovirus in each of clades B (T/F), C, C (T/F), BC, A
(T/F), CRF02_AG, CRF01_AE, CRF01_AE (T/F), G, and CD at at an
IC.sub.50 of less than or about 0.1 .mu.g/m1 (FIG. 4). In some
embodiments, the binding agent comprises any one or more of these
properties and one or more of SEQ ID NOS. 1-32, preferably each of
SEQ ID NOS. 1-7 and/or SEQ ID NOS. 8-9 and/or fragments and/or
derivatives thereof. These are characteristics of LN01-type binding
agents, such as IgG1 LN01, as shown in FIG. 4.
[0038] In some embodiments, the binding agents may be tested for
neutralization capacity against HIV reference pseudoviruses (e.g.,
the above-described Global Panel of nine (9) HIV-1 reference
pseudoviruses) using cells expressing or not expressing one or more
types of Fc receptors (e.g., parental TZM-bl cells and TZM-bl cells
expressing Fc-gamma receptor I (CD64) as in the examples; see e.g.
Perez, et al. Utilization of immunoglobulin G Fc receptors by human
immunodeficiency virus type 1: a specific role for antibodies
against the membrane-proximal external region of gp41. J Virol 83,
7397-7410 (2009); NIH AIDS Reagent Program Catalog No. 11798).
Enhanced neutralizing activity in cells expressing Fc receptors may
provide antibodies a kinetic advantage for virus inhibition. This
kinetic advantage could be unique to antibodies, whose epitopes are
thought to be difficult to access or exposed for only a short time
on intermediate conformations of the Env protein during an early
stage of fusion. Fc-gamma receptors could also potentially
facilitate HIV-1 neutralization is phagocytosis, thereby increasing
neutralization capacity of the antibodies. To this point, HeLa
cells, from which the TZM-bl cell line was constructed, are known
to exhibit properties of nonprofessional phagocytes. Thus, it is
possible that TZM-bl cells were converted to professional
phagocytic cells by introducing Fc-gamma receptor on their surface.
Any Fc-gamma-receptor-mediated antiviral effects on HIV-1
neutralizing antibodies, whether by entry inhibition or
phagocytosis, might be beneficial in HIV treatment and vaccine
regimens. Fc-gamma receptors are rarely expressed on CD4+
lymphocytes, but several other HIV-1-susceptible cell types express
multiple Fc-gamma receptors and are involved in sexual transmission
and the early establishment of long-lived viral reservoirs. In
particular, macrophages are among the first infection-susceptible
cells that the virus encounters after mucosal exposure, and are
thought to serve as a long-lived virus reservoir in chronic
infection. Macrophages, as well as certain subsets of monocytes and
dendritic cells, are known to express multiple Fc-gamma receptors.
It is also important to mention that Fc-gamma receptors play a role
in regulating adaptive immunity and peripheral tolerance, by
facilitating antigen uptake, antigen presentation, cell activation
and B cell tolerance. Thus, is some embodiments, the binding agents
described herein may be used in conjunction with agents that induce
and/or enhance Fc receptor expression, including the introduction
of nucleic acids encoding one or more Fc receptors with or in
conjunction with treatment by the binding agents described
herein.
[0039] The specificity of the binding agents described herein may
be determined using any of the many techniques available to those
of ordinary skill in the art. For instance, as shown in the
examples herein, the specificity of a binding agent (e.g., IgG1
LN01 antibody), with respect to particular epitopes, may be
ascertained using a panel of chimeric pseudoviruses (e.g.,
HIV-2/HIV-1 chimeras containing various segments of the HIV-1 MPER
into the parental HIV-2/7312A) to test for neutralization capacity.
For instance, the examples herein demonstrate that IgG1 LN01
antibody does not neutralize the parental HIV-2 7312A strain.
However, IgG1 LN01 antibody was found to potently neutralize the
chimeric virus 7312A.C4 in which six (6) residues of HIV-2 MPER
(LASWVKYIQ (SEQ ID NO. 65)) were replaced by those of HIV-1 MPER
region (ITKWLWYIK (SEQ ID NO. 66)). IgG1 LN01 antibodies was also
found not to neutralize the chimeric virus 7312A.C6 in which only
three (3) residues in the same region were replaced (ITSWIKYIQ (SEQ
ID NO. 67)) (see, e.g., FIG. 7). A similar finding was obtained
with the chimeric virus 7312A.C1C where the same six (6) changes to
7312A.C4 were combined with an additional seven (7) mutations in
the N-terminal region. These results indicate that amino acid
residues L679, W680 and K683 in the C-terminal region of gp41 MPER
are involved in IgG1 LN01 antibody binding. Thus, in some
embodiments, the binding agent exhibits the capacity to bind to
and/or neutralize HIV expressing gp41 comprising the amino acid
residues L679, W680 and K683 as found in the HIV-1 envelope amino
acid sequence of GenBank Accession No. K03455 (NCBI GenPept
Accession No. AAB50262), such as, for instance, SEQ ID NO. 68
(L679, W680 and K683 underlined):
TABLE-US-00002 (SEQ ID NO. 68) 1 MRVKEKYQHL WRWGWRWGTM LLGMLMICSA
TEKLWVTVYY GVPVWKEATT TLFCASDAKA 61 YDTEVHNVWA THACVPTDPN
PQEVVLVNVT ENFNMWKNDM VEQMHEDIIS LWDQSLKPCV 121 KLTPLCVSLK
CTDLKNDTNT NSSSGRMIME KGEIKNCSFN ISTSIRGKVQ KEYAFFYKLD 181
IIPIDNDTTS YKLTSCNTSV ITQACPKVSF EPIPIHYCAP AGFAILKCNN KTFNGTGPCT
241 NVSTVQCTHG IRPVVSTQLL LNGSLAEEEV VIRSVNFTDN AKTIIVQLNT
SVEINCTRPN 301 NNTRKRIRIQ RGPGRAFVTI GKIGNMRQAH CNISRAKWNN
TLKQIASKLR EQFGNNKTII 361 FKQSSGGDPE IVTHSFNCGG EFFYCNSTQL
FNSTWFNSTW STEGSNNTEG SDTITLPCRI 421 KQIINMWQKV GKAMYAPPIS
GQIRCSSNIT GLLLTRDGGN SNNESEIFRP GGGDMRDNWR 481 SELYKYKVVK
IEPLGVAPTK AKRRVVQREK RAVGIGALFL GFLGAAGSTM GAASMTLTVQ 541
ARQLLSGIVQ QQNNLLRAIE AQQHLLQLTV WGIKQLQARI LAVERYLKDQ QLLGIWGCSG
601 KLICTTAVPW NASWSNKSLE QIWNHTTWME WDREINNYTS LIHSLIEESQ
NQQEKNEQEL 661 LELDKWASLW NWFNITNWLW YIKLFIMIVG GLVGLRIVFA
VLSIVNRVRQ GYSPLSFQTH 721 LPTPRGPDRP EGIEEEGGER DRDRSIRLVN
GSLALIWDDL RSLCLFSYHR LRDLLLIVTR 781 IVELLGRRGW EALKYWWNLL
QYWSQELKNS AVSLLNATAI AVAEGTDRVI EVVQGACRAI 841 RHIPRRIRQG
LERILL,
or equivalents thereof as would be understood by those of ordinary
skill in the art. An exemplary gp41 polypeptide is shown below:
TABLE-US-00003 (SEQ ID NO. 69)
AVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQ
QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKD
QQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNNMTW
MEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWA
SLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVN RVRQG.
Another exemplary gp41 polypeptide has GenBank Accession No.
1103299B (Meusing, et al. Nature 313 (6002), 450-458 (1985)).
Exemplary equivalents to amino acid residues L679, W680 and K683
are the underlined amino acid residues L168, W169 and K172 of SEQ
ID NO. 14 (as well as GenBank Accession No. 1103299B). In some
embodiments, the binding agent exhibits the capacity to bind to
and/or neutralize HIV expressing amino acid sequence ITKWLWYIK (SEQ
ID NO. 66). In some embodiments, the binding agent exhibits the
capacity to bind to and/or neutralize HIV expressing amino acid
sequence ITKWLWYIK (SEQ ID NO. 66) but not LASWVKYIQ (SEQ ID NO.
65) and/or ITKWIKYIQ (SEQ ID NO. 67). In some embodiments, the
epitope(s) to which the binding agent binds (i.e., has specificity)
includes the amino acid residues L679, W680 and K683, or
equivalents thereof of, HIV env (e.g., SEQ ID NO. 68. Wth respect
gp41, in preferred embodiments, the epitope(s) to which the binding
agent binds (i.e., has specificity) includes the amino acid
residues L168, W169 and K172 of SEQ ID NO. 69, or equivalents
thereof. In some embodiments, a binding agent of this disclosure
may comprise these binding specificities along with the
neutralization characteristics described above (i.e.,
neutralization of HIV-1 pseudoviruses BJOX (CRF07_BC), CE1176,
TRO.11 (B), X1632 (G), CH119 (CRF07_BC), CNE55 (CRF01_AE), 25710
(C), CD0217(C) but not of the control virus SVA-MLV at a
concentration is from 10.sup.2-10.sup.0 ug/ml, or between
10.sup.0-10.sup.1 ug/ml, to at least about 50% (FIG. 3), as well as
the neutralization a majority of the 118 HIV-1 pseudoviruses listed
in FIG. 4 at an IC.sub.50 of less than 25 .mu.g/ml).
[0040] Peptide microarrays may alternatively and/or also be used to
determine the binding specificity of the binding agents described
herein. One or more peptide microarrays may be designed such that
overlapping peptides encompassing the entire amino acid sequence of
a HIV polypeptide. For instance, as shown in the examples herein, a
peptide microarray formed by 1423 overlapping (by 12 amino acids)
15-mer peptides covering the consensus HIV-1 Env gp160 sequences
for clades A, B, C, D, group M, CRF01_AE and CRF02_AG was utilized
to test the specificity of binding agent IgG1 LN01. In the examples
herein, the peptides were printed onto 3D-Epoxy glass slides and
were analyzed with a GenePix 4000B scanner (Tomaras, G. D. et al.
Polyclonal B cell responses to conserved neutralization epitopes in
a subset of HIV-1-infected individuals. J Virol 85, 11502-11519
(2011)) but any suitable system available to those of ordinary
skill in the art may be utilized. The binding agent may be tested
along with a control binding agent (e.g., in the examples herein
IgG01 LN01 was tested at 20 .mu.g/ml in parallel with a control
antibody called 7B2 haivng specificity for the immunodominant
region of gp41). The binding of the binding agent to the peptides
in the microarray may be detected by any suitable process,
including by incubation with DyLight 649-labeled goat anti-human
IgG as in the examples herein. Fluorescence intensity may be
measured by any suitable system, such as a GenePix 4000B
scanner/GenePix software as in the examples herein (see, e.g., FIG.
8). As shown in the examples herein, IgG1 LN01 antibody did not
clearly react with any of the peptides in that library, while the
control antibody (7B2) strongly reacted with 190-195 peptides that
spanned the gp41 immunodominant region, indicating that the IgG1
LN01 antibody does not recognize a linear epitope in HIV-1 Env.
Similar tests may also be performed on any of the binding agents
contemplated herein.
[0041] The specificity of a binding agent may also be tested for
binding to soluble trimers representing HIV proteins (e.g.,
soluble, cleaved SOSIP.664 gp140 trimers based on the subtype A
transmitted/founder strain, BG505 as used in the examples herein).
Preferred trimers (such as those used in the examples herein) are
those being highly stable, homogenous and closely resembling native
virus spikes when visualized by negative stain electron microscopy
(EM) (Sanders, R. W. et al. A next-generation cleaved, soluble
HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple
epitopes for broadly neutralizing but not non-neutralizing
antibodies. PLoS Pathog. 9, e1003618 (2013)). Typically, broadly
neutralizing antibodies against multiple neutralizing epitopes on
HIV-1 Env will be highly reactive with such trimers (e.g., the
BG505 SOSIP.664 gp140 trimers, including quaternary epitopes
antibodies (CH01, PG9, PG16 and PGT145)). Conversely,
non-neutralizing antibodies (NAbs) to the CD4-binding site,
CD4-induced epitopes or gp41 ectodomain would not (and did not in
the example) react with the trimers, even when their epitopes were
present on simpler forms of Env (e.g., gp120 monomers or
dissociated gp41 subunits). The examples also included a test,
which may be used in testing any of binding agents described
herein, in which the MPER was also deleted to improve trimer
solubility and reduce aggregate formation. The binding agents may
also be tested for binding to such trimers in the presence or
absence of soluble CD4 (sCD4). The examples herein describe the
testing of the IgG1 LN01, PGT145 (V1-V2 glycan specific), PGT151
(binding to a site at the interface between gp120 and gp41) and 17b
(binding to a CD4 binding induced site) antibodies for binding to
BG505 SOSIP.664 gp140 trimers in the presence or absence of sCD4
(measured by surface plasmon resonance (SPR)). As shown therein,
the PGT145 and PGT151 antibodies reacted strongly to BG505
SOSIP.664 gp140 trimers in the presence and absence of sCD4; 17b
reacted to BG505 SOSIP.664 gp140 trimers only in the presence of
sCD4; and IgG1 LN01 did not react with BG505 SOSIP.664 gp140
trimers neither in the presence nor in the absence of sCD4 (see,
e.g., FIG. 9). Similar tests may also be performed on any of the
binding agents contemplated herein.
[0042] Other assay systems such as ELISA may also be used to test
the binding agents contemplated herein. For instance, as shown in
the examples, the IgG1 LN01 antibody, in parallel with
MPER-specific 10E8 antibody (Huang, J. et al. Broad and potent
neutralization of HIV-1 by a gp41-specific human antibody. Nature
491, 406-412 (2012)), was tested by ELISA against a panel of HIV-1
antigens (ConsB, consensus clade B gp140, 426c, clade C gp140,
426c-NLGS, 426c gp140 where the N-linked glycosylation sites were
removed, 426c core, gp140 where the V loops were removed, UG37
gp140, clade A and gp41, recombinant ecto-domain of gp41, amino
acids 541-682 from HxB2 strain, Vybion). None of the tested
antigens was recognized by IgG1 LN01 antibody by ELISA (see, e.g.,
FIG. 10). Conversely, 10E8 antibody reacted to the recombinant
ecto-domain of gp41. The results presented in the examples
therefore indicate that IgG1 LN01 antibody might recognize an
epitope in the MPER of gp41 different from 10E8. The examples
herein also demonstrate the testing of IgG1 LN01 antibody against a
fusion intermediate gp41 and uncoated plates (PBS), called gp41int
(Lai, R. P. J. et al. A fusion intermediate gp41 immunogen elicits
neutralizing antibodies to HIV-1. J Biol Chem 289, 29912-29926
(2014)), using ELISA. The gp41int antigen is recognized with high
affinity by MPER antibodies 4E10, 2F5 and 10E8. While 10E8 reacted
to gp4lint by ELISA, IgG1 LN01 antibody did not (see, e.g., FIG.
11). These results indicate that IgG1 LN01 antibody recognizes a
conserved epitope, possibly in the MPER region, that is not readily
displayed in any of the antigens tested. Similar tests may be
performed on any of the binding agents contemplated herein.
[0043] The term "binding affinity" and/or K.sub.D refers to the
dissociation rate of a particular antibody-antigen interaction. The
K.sub.D is the ratio of the rate of dissociation ("off-rate
(k.sub.d)") to the association rate ("on-rate (k.sub.a)). K.sub.D
therefore equals k.sub.d/k.sub.a and is expressed as a molar
concentration (M). Thus, the smaller the K.sub.D, the stronger the
affinity of binding. For example, a a K.sub.D of 1 mM indicates
weak binding as compared to a K.sub.D of 1 nM. K.sub.D values for
antibodies can be determined using methods well established in the
art such as by using a Biacore.RTM. system. In some embodiments,
the binding agents described herein may be compared with another
binding agent with reference to the respective K.sub.D values of
each. These properties may be combined with other characteristics
such as neutralization capacity and/or epitope specificity in order
to compare binding agents to one another. Accordingly, binding
agents having a similar K.sub.D to those described herein, perhaps
also sharing the neutralization capacity and epitope specificity
described herein (e.g., as exhibited by LN01), are also
contemplated as part of this disclosure.
[0044] Any of the amino acid sequences of Tables 1 (and/or any one
or more fragments and/or derivatives thereof) may be also
substituted by any other amino acid as desired by one of ordinary
skill in the art. For example, one of skill in the art may make
conservative substitutions by replacing particular amino acids with
others as shown in Table 2 below. The specific amino acid
substitution selected may depend on the location of the site
selected. An amino acid substitution may be said to "correspond to"
where one of ordinary skill in the art could ascertain a
significant amount of similarity between the amino acid sequences
surrounding the amino acid being substituted. For instance, a
particular amino acid sequence may correspond to another where two,
three, four or more N-terminal and C-terminal amino acids
surrounding the amino acid being substituted are the same or
similar (e.g., as described in Table 2) in the polypeptides being
compared. Conservative amino acid substitutions may involve a
substitution of a native amino acid residue with a non-native
residue such that there is little or no effect on the size,
polarity, charge, hydrophobicity, or hydrophilicity of the amino
acid residue at that position and, in particular, does not result
in, e.g., decreased HIV neutralization capacity and/or different
epitope specificity.
TABLE-US-00004 TABLE 2 Original Preferred Conservative Amino
Exemplary Conservative Substitutions of the Acid Substitution of
the Original Original Amino Residue Amino Acid Residue Acid Residue
Ala Val, Leu, Ile Val Arg Lys, Gln, Asn Lys Asn Gln Gln Asp Glu Glu
Cys Ser, Ala Ser Gln Asn Asn Glu Asp Asp Gly Pro, Ala Ala His Asn,
Gln, Lys, Arg Arg Ile Leu, Val, Met, Ala, Phe, Norleucine Leu Leu
Norleucine, Ile, Val, Met, Ala, Phe Ile Lys Arg, 1,4
Diamino-butyric Acid, Gln, Asn Arg Met Leu, Phe, Ile Leu Phe Leu,
Val, Ile, Ala, Tyr Leu Pro Ala Gly Ser Thr, Ala, Cys Thr Thr Ser
Ser Trp Tyr, Phe Tyr Tyr Trp, Phe, Thr, Ser Phe Val Ile, Met, Leu,
Phe, Ala, Norleucine Leu
[0045] In certain embodiments, a nucleic acid molecule encoding one
or more binding agents described herein may be inserted into one or
more expression vectors, as discussed below in greater detail. In
such embodiments, the binding agent may be encoded by nucleotides
corresponding to the amino acid sequence. The particular
combinations of nucleotides (codons) that encode the various amino
acids (AA) are well known in the art, as described in various
references used by those skilled in the art (e.g., Lewin, B. Genes
V, Oxford University Press, 1994). The nucleotide sequences
encoding the amino acids of said binding agents may be ascertained
with reference to Table 3, for example. Nucleic acid variants may
use any combination of nucleotides that encode the binding
agent.
TABLE-US-00005 TABLE 3 Codons Encoding Amino Acids (AA) AA Codon AA
Codons AA Codons AA Codons Phe TTT Ser TCT Tyr TAT Cys (C) TGT (F)
TTC (S) TCC (Y) TAC TGC Leu TTA TCA TERM TAA TERM TGA (L) TTG TCG
TAG Trp (W) TGG CTT Pro CCT His CAT Arg (R) CGT CTC (P) CCC (H) CAC
CGC CTA CCA Gin CAA CGA CTG CCG (Q) CAG CGG Ile ATT Thr ACT Asn AAT
Ser (S) AGT (I) ATC (T) ACC (N) AAC AGC ATA ACA Lys AAA Arg (R) AGA
Met ATG ACG (K) AAG AGG (M) Val GTT Ala GCT Asp GAT Gly (G) GGT (V)
GTC (A) GCC (D) GAC GGC GTA GCA Glu GAA GGA GTG GCG (E) GAG GGG
Those of ordinary skill in the art understand that the nucleotide
sequence encoding a particular amino acid sequence may be easily
derived from the amino acid sequence of any of SEQ ID NOS. 1-7 and
the information presented in Table 4. For instance, it may be
deduced from the amino acid sequence GDSVSNDNYY (SEQ ID NO.: 1) and
the information presented in Table 4 that the amino acid sequence
may be encoded by the nucleotide sequence
GGTGACTCAGTCAGTAATGATAATTATTAT (SEQ ID NO.: 33). Those of ordinary
skill in the art would understand that nucleotide sequences
encoding SEQ ID NOS. 2-32 and 34-36 may be deduced in the same way,
and such nucleotide sequences are contemplated herein. Table 4
provides exemplary nucleic acid sequences encoding the amino acid
sequences shown in Table 1 (SEQ ID NOS. 1-32):
TABLE-US-00006 TABLE 4 Exemplary Nucleotide LN01 region Amino
Sequence Sequence LN01 CDRH1 GDSVSNDNYY GGTGACTCAGTCAGTAATGATA (SEQ
ID NO. 1) ATTATTAT (SEQ ID NO. 33) LN01 CDRH2 IYYSGTT
ATCTATTACAGCGGCACAACC (SEQ ID NO. 2) (SEQ ID NO. 34) LN01 CDRH3
VRMPSHGFWSTSFSYWYF GTTCGCATGCCCAGTCACGGAT DL (SEQ ID NO. 3)
TTTGGAGTACTTCTTTCTCTTAC TGGTATTTCGATCTC(SEQ ID NO. 35) LN01 CDRL1
QSVTKY CAGAGTGTCACCAAATAT(SEQ (SEQ ID NO. 4) ID NO. 36) LN01 CDRL2
GTY GGGACTTAT LN01 CDRL2 (long) LIYGTYTLL CTCATCTATGGGACTTATACTT
(SEQ ID NO. 5) TACTC(SEQ ID NO. 37) LN01 CDR3 QQAHSTPWT
CAACAGGCTCACAGTACTCCC (SEQ ID NO. 6) TGGACC (SEQ ID NO. 38) LN01
Variable Heavy EVQLVESGPGLVQPWGTLSL GAGGTGCAGCTGGTGGAGTCG (V.sub.H)
TCRVSGDSVSNDNYYWAWI GGCCCAGGACTGGTGCAGCCC RQTPGRELQVIGTIYYSGTTY
TGGGGGACCCTGTCCCTCACCT YNPSLRNRVTISLDKSVNVVS GTCGTGTCTCTGGTGACTCAGT
LRLGSVSAADTAQYYCVRMP CAGTAATGATAATTATTATTGGG SHGFWSTSFSYWYFDLWGR
CCTGGATTCGCCAGACCCCCGG GHFVAVSW GAGGGAACTGCAGGTCATCGGA (SEQ ID NO.
7) ACTATCTATTACAGCGGCACAAC CTACTACAATCCGTCGCTCAGG
AATCGAGTCACGATCTCATTGG ACAAGTCCGTCAATGTGGTCTC
CCTGAGATTGGGGTCTGTGAGT GCCGCGGACACGGCCCAATATT
ATTGCGTTCGCATGCCCAGTCA CGGATTTTGGAGTACTTCTTTCT
CTTACTGGTATTTCGATCTCTGG GGCCGTGGTCATTTCGTCGCTG TCTCCTGG (SEQ ID NO.
39) LN01 Variable Light DIQMTQSPSSLSASVGDKVTI
GACATCCAGATGACCCAGTCTC (V.sub.L) TCRASQSVTKYLNWYQFKT
CGTCCTCCCTGTCTGCCTCTGT GQAPRILIYGTYTLLSGVSPR TGGAGACAAAGTCACCATCACC
FSGAGSGSLYTLTITNIQPED TGCCGGGCCAGTCAGAGTGTCA FATYYCQQAHSTPWTFGQG
CCAAATATTTAAATTGGTATCAG THVAAN TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO.
8) GAATCCTCATCTATGGGACTTAT ACTTTACTCAGTGGCGTCTCGC
CTCGGTTCAGTGGCGCCGGATC TGGTTCACTCTACACTCTGACCA
TCACCAATATACAGCCTGAAGA CTTCGCCACCTATTATTGTCAAC
AGGCTCACAGTACTCCCTGGAC CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID NO.
40) LN01 variant 7 EVQLVESGPGLVQPWGTLSL GAAGTGCAGCTGGTGGAATCTG
Variable Heavy (V.sub.H) TCRVSGDSVSNWNYYWAWI GCCCTGGCCTGGTGCAGCCTTG
(CDRH1, CDRH2 RQTPGRELQVIGTIYYSGTTY GGGCACACTGAGCCTGACCTGT and
CDRH3 YNPSLRNRVTISLDKSVNVVS AGAGTGTCCGGCGACAGCGTGT underlined)
LRLGSVSAADTAQYYCVRMP CCAACTGGAACTACTACTGGGC SHGFWSTSFSYWYFDLWG
CTGGATCCGGCAGACCCCCGG RGHFVAVSW CAGAGAACTGCAAGTGATCGGC (SEQ ID NO.:
9) ACCATCTACTACAGCGGCACAA CCTACTACAACCCCAGCCTGCG
GAACAGAGTGACCATCAGCCTG GACAAGAGCGTGAACGTGGTGT
CCCTGAGACTGGGCTCTGTGTC TGCCGCCGATACCGCCCAGTAC
TACTGCGTGCGGATGCCCAGCC ACGGCTTCTGGTCTACCAGCTT
CAGCTACTGGTACTTCGACCTG TGGGGCAGAGGCCACTTCGTG GCCGTGTCTTGG (SEQ ID
NO. 41) LN01 variant 7 DIQMTQSPSSLSASVGDKVTI GACATCCAGATGACCCAGTCTC
Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT CGTCCTCCCTGTCTGCCTCTGT
(CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR TGGAGACAAAGTCACCATCACC
CDRL3 underlined) FSGAGSGSLYTLTITNIQPED TGCCGGGCCAGTCAGAGTGTCA
FATYYCQQAHSTPWTFGQG CCAAATATTTAAATTGGTATCAG THVAAN
TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO.: 10) GAATCCTCATCTATGGGACTTAT
ACTTTACTCAGTGGCGTCTCGC CTCGGTTCAGTGGCGCCGGATC
TGGTTCACTCTACACTCTGACCA TCACCAATATACAGCCTGAAGA
CTTCGCCACCTATTATTGTCAAC AGGCTCACAGTACTCCCTGGAC
CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID NO. 42) LN01 variant 8
EVQLVESGPGLVQPWGTLSL GAAGTGCAGCTGGTGGAATCTG Variable Heavy
(V.sub.H) TCRVSGDSVSNDWYYWAWI GCCCTGGCCTGGTGCAGCCTTG (CDRH1, CDRH2
RQTPGRELQVIGTIYYSGTTY GGGCACACTGAGCCTGACCTGT and CDRH3
YNPSLRNRVTISLDKSVNVVS AGAGTGTCCGGCGACAGCGTGT underlined)
LRLGSVSAADTAQYYCVRMP CCAACGACTGGTACTACTGGGC SHGFWSTSFSYWYFDLWGR
CTGGATCCGGCAGACCCCCGG GHFVAVSW CAGAGAACTGCAAGTGATCGGC (SEQ ID NO.:
11) ACCATCTACTACAGCGGCACAA CCTACTACAACCCCAGCCTGCG
GAACAGAGTGACCATCAGCCTG GACAAGAGCGTGAACGTGGTGT
CCCTGAGACTGGGCTCTGTGTC TGCCGCCGATACCGCCCAGTAC
TACTGCGTGCGGATGCCCAGCC ACGGCTTCTGGTCTACCAGCTT
CAGCTACTGGTACTTCGACCTG TGGGGCAGAGGCCACTTCGTG GCCGTGTCTTGG (SEQ ID
NO. 43) LN01 variant 8 DIQMTQSPSSLSASVGDKVTI GACATCCAGATGACCCAGAGCC
Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT CCAGCAGCCTGTCTGCCAGCGT
(CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR GGGCGACAAAGTGACCATCACC
CDRL3 underlined) FSGAGSGSLYTLTITNIQPED TGTCGGGCCAGCCAGAGCGTG
FATYYCQQAHSTPWTFGQG ACCAAGTACCTGAACTGGTATC THVAAN
AGTTTAAGACCGGCCAGGCCCC (SEQ ID NO.: 12) CAGAATCCTGATCTACGGCACC
TACACCCTGCTGAGCGGCGTGT CCCCTAGATTCTCTGGCGCCGG
AAGCGGCAGCCTGTACACCCTG ACAATCACCAACATCCAGCCCG
AGGACTTCGCCACCTACTACTG CCAGCAGGCCCACAGCACCCCT
TGGACATTTGGCCAGGGAACAC ACGTGGCCGCCAAC (SEQ ID NO. 44) LN01 variant
38 EVQLVESGPGLVQPWGTLSL AAGTGCAGCTGGTGGAATCTGG Variable Heavy
(V.sub.H) TCRVSGDSVSNDNYYWAWI CCCTGGCCTGGTGCAGCCTTGG (CDRH1, CDRH2
RQTPGRELQVIGTIYYSGTTY GGCACACTGAGCCTGACCTGTA and CDRH3
YNPSLRNRVTISLDKSVNVVS GAGTGTCCGGCGACAGCGTGTC underlined)
LRLGSVSAADTAQYYCVRMP CAACGACAACTACTACTGGGCC SHGFWSTSFSYWYFDLWGR
TGGATCCGGCAGACCCCCGGC GHFVAVSW AGAGAACTGCAAGTGATCGGCA (SEQ ID NO.:
13) CCATCTACTACAGCGGCACAAC CTACTACAACCCCAGCCTGCGG
AACAGAGTGACCATCAGCCTGG ACAAGAGCGTGAACGTGGTGTC
CCTGAGACTGGGCTCTGTGTCT GCCGCCGATACCGCCCAGTACT
ACTGCGTGCGGATGCCCAGCCA CGGCTTCTGGTCTACCAGCTTC
AGCTACTGGTACTTCGACCTGT GGGGCAGAGGCCACTTCGTGG CCGTGTCTTGG(SEQ ID NO.
45) LN01 variant 38 DIQMTQSPSSLSASVGDKVTI ACATCCAGATGACCCAGAGCCC
Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT CAGCAGCCTGTCTGCCAGCGTG
(CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR GGCGACAAAGTGACCATCACCT
CDRL3 underlined) FSGAGWGSLYTLTITNIQPED GTCGGGCCAGCCAGAGCGTGA
FATYYCQQAHSTPWTFGQG CCAAGTACCTGAACTGGTATCA THVAAN
GTTTAAGACCGGCCAGGCCCCC (SEQ ID NO.: 14) AGAATCCTGATCTACGGCACCT
ACACCCTGCTGAGCGGCGTGTC CCCTAGATTCTCTGGCGCCGGA
TGGGGCAGCCTGTACACCCTGA CAATCACCAACATCCAGCCCGA
GGACTTCGCCACCTACTACTGC CAGCAGGCCCACAGCACCCCTT
GGACATTTGGCCAGGGAACACA CGTGGCCGCCAAC (SEQ ID NO. 46) LN01 variant
41 EVQLVESGPGLVQPWGTLSL GAGGTGCAGCTGGTGGAATCTG Variable Heavy
(V.sub.H) TCRVSGDSVSNFNYYWAWI GACCTGGACTGGTGCAGCCTTG (CDRH1, CDRH2
RQTPGRELQVIGTIYYSGTTY GGGCACTCTGTCTCTGACATGC and CDRH3
YNPSLRNRVTISLDKSVNVVS CGGGTGAGCGGGGACAGCGTC underlined)
LRLGSVSAADTAQYYCVRMP TCCAACTTTAATTACTATTGGGC SHGFWSTSFSYWYFDLWGR
TTGGATCAGGCAGACACCAGGG GHFVAVSW CGCGAGCTGCAGGTCATCGGG (SEQ ID NO.:
15) ACTATCTACTATTCCGGAACCAC ATACTATAACCCCTCTCTGCGGA
ATAGAGTGACCATTTCTCTGGAC AAGAGTGTCAACGTGGTCAGTC
TGCGACTGGGATCTGTGAGTGC CGCTGATACCGCACAGTACTAT
TGCGTGCGGATGCCCTCTCACG GCTTCTGGTCAACAAGCTTTTCC
TACTGGTATTTCGATCTGTGGG GACGGGGCCATTTCGTGGCCGT CTCCTGG (SEQ ID NO.
47) LN01 variant 41 DIQMTQSPSSLSASVGDKVTI GACATCCAGATGACCCAGTCTC
Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT CGTCCTCCCTGTCTGCCTCTGT
(CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR TGGAGACAAAGTCACCATCACC
CDRL3 underlined) FSGAGSGSLYTLTITNIQPED TGCCGGGCCAGTCAGAGTGTCA
FATYYCQQAHSTPWTFGQG CCAAATATTTAAATTGGTATCAG THVAAN
TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO.: 16) GAATCCTCATCTATGGGACTTAT
ACTTTACTCAGTGGCGTCTCGC CTCGGTTCAGTGGCGCCGGATC
TGGTTCACTCTACACTCTGACCA TCACCAATATACAGCCTGAAGA
CTTCGCCACCTATTATTGTCAAC AGGCTCACAGTACTCCCTGGAC
CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID NO. 48) LN01 variant 42
EVQLVESGPGLVQPWGTLSL GAGGTGCAGCTGGTGGAATCTG Variable Heavy
(V.sub.H) TCRVSGDSVSNYNYYWAWI GACCTGGACTGGTGCAGCCTTG (CDRH1, CDRH2
RQTPGRELQVIGTIYYSGTTY GGGCACTCTGTCTCTGACATGC and CDRH3
YNPSLRNRVTISLDKSVNVVS CGGGTGAGCGGGGACAGCGTC underlined)
LRLGSVSAADTAQYYCVRMP TCCAACTACAATTACTATTGGGC SHGFWSTSFSYWYFDLWGR
TTGGATCAGGCAGACACCAGGG GHFVAVSW CGCGAGCTGCAGGTCATCGGG (SEQ ID NO.:
17) ACTATCTACTATTCCGGAACCAC ATACTATAACCCCTCTCTGCGGA
ATAGAGTGACCATTTCTCTGGAC AAGAGTGTCAACGTGGTCAGTC
TGCGACTGGGATCTGTGAGTGC CGCTGATACCGCACAGTACTAT
TGCGTGCGGATGCCCTCTCACG GCTTCTGGTCAACAAGCTTTTCC
TACTGGTATTTCGATCTGTGGG GACGGGGCCATTTT GTGGCCGT CTCCTGG (SEQ ID NO.
49) LN01 variant 42 DIQMTQSPSSLSASVGDKVTI GACATCCAGATGACCCAGTCTC
Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT CGTCCTCCCTGTCTGCCTCTGT
(CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR TGGAGACAAAGTCACCATCACC
CDRL3 underlined) FSGAGSGSLYTLTITNIQPED TGCCGGGCCAGTCAGAGTGTCA
FATYYCQQAHSTPWTFGQG CCAAATATTTAAATTGGTATCAG THVAAN
TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO.: 18) GAATCCTCATCTATGGGACTTAT
ACTTTACTCAGTGGCGTCTCGC CTCGGTTCAGTGGCGCCGGATC
TGGTTCACTCTACACTCTGACCA TCACCAATATACAGCCTGAAGA
CTTCGCCACCTATTATTGTCAAC AGGCTCACAGTACTCCCTGGAC
CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID NO. 50) LN01 variant 48
QLQLQESGPGLVKPSETLSL CAGCTGCAGCTGCAGGAGAGTG Variable Heavy
(V.sub.H) TCTVSGDSVSNWNYYWAWI GACCTGGACTGGTGAAGCCTTC (CDRH1, CDRH2
RQTPGRELQVIGTIYYSGTTY AGAAACACTGAGCCTGACTTGC and CDRH3
YNPSLRNRVTISLDKSVNVVS ACCGTGTCCGGCGACTCTGTCA underlined)
LRLGSVSAADTAQYYCVRMP GTAACTGGAATTACTATTGGGCA SHGFWSTSFSYWYFDLWGR
TGGATTAGACAGACACCAGGAA GTLVTVSS GAGAGCTGCAGGTCATCGGGAC (SEQ ID NO.:
19) AATCTACTATAGTGGAACCACAT ACTATAACCCCTCACTGCGGAA
TAGAGTGACCATTTCCCTGGAC AAATCTGTCAACGTGGTCTCTCT
GCGACTGGGCTCAGTGAGCGC CGCTGATACTGCCCAGTACTATT GCGTGCGGATGCCCAGCCACG
GCTTCTGGTCCACCTCTTTTAGT TACTGGTATTTCGATCTGTGGG
GACGGGGCACACTGGTGACTGT CAGCTCC (SEQ ID NO. 51) LN01 variant 48
DIQMTQSPSSLSASVGDKVTI GACATCCAGATGACCCAGTCTC Variable Light
(V.sub.L) TCRASQSVTKYLNWYQFKT CGTCCTCCCTGTCTGCCTCTGT (CDRL1, CDRL2
and GQAPRILIYGTYTLLSGVSPR TGGAGACAAAGTCACCATCACC CDRL3 underlined)
FSGAGSGSLYTLTITNIQPED TGCCGGGCCAGTCAGAGTGTCA FATYYCQQAHSTPWTFGQG
CCAAATATTTAAATTGGTATCAG THVAAN TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO :
20) GAATCCTCATCTATGGGACTTAT ACTTTACTCAGTGGCGTCTCGC
CTCGGTTCAGTGGCGCCGGATC TGGTTCACTCTACACTCTGACCA
TCACCAATATACAGCCTGAAGA CTTCGCCACCTATTATTGTCAAC
AGGCTCACAGTACTCCCTGGAC CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID NO.
52) LN01 variant 49 EVQLVESGPGLVQPWGTLSL GAGGTGCAGCTGGTGGAATCTG
Variable Heavy (V.sub.H) TCRVSGDSVSNWWYYWAWI GACCTGGACTGGTGCAGCCTTG
(CDRH1, CDRH2 RQTPGRELQVIGTIYYSGTTY GGGCACTCTGTCTCTGACATGC and
CDRH3 YNPSLRNRVTISLDKSVNVVS CGGGTGAGCGGGGACAGCGTC underlined)
LRLGSVSAADTAQYYCVRMP TCCAACTGGTGGTACTATTGGG SHGFWSTSFSYWYFDLWGR
CTTGGATCAGGCAGACACCAGG GHFVAVSW GCGCGAGCTGCAGGTCATCGG (SEQ ID NO.:
21) GACTATCTACTATTCCGGAACCA CATACTATAACCCCTCTCTGCG
GAATAGAGTGACCATTTCTCTG GACAAGAGTGTCAATGTGGTCA
GTCTGCGACTGGGATCTGTGAG TGCCGCTGATACCGCACAGTAC
TATTGCGTGCGGATGCCCTCTC ACGGCTTCTGGTCAACAAGCTT
TTCCTACTGGTATTTCGATCTGT GGGGACGGGGCCATTTTGTGG CCGTCTCCTGG (SEQ ID
NO.: 53) LN01 variant 49 DIQMTQSPSSLSASVGDKVTI
GACATCCAGATGACCCAGTCTC Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT
CGTCCTCCCTGTCTGCCTCTGT (CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR
TGGAGACAAAGTCACCATCACC CDRL3 underlined) FSGAGSGSLYTLTITNIQPED
TGCCGGGCCAGTCAGAGTGTCA FATYYCQQAHSTPWTFGQG CCAAATATTTAAATTGGTATCAG
THVAAN TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO.: 22)
GAATCCTCATCTATGGGACTTAT ACTTTACTCAGTGGCGTCTCGC
CTCGGTTCAGTGGCGCCGGATC TGGTTCACTCTACACTCTGACCA
TCACCAATATACAGCCTGAAGA CTTCGCCACCTATTATTGTCAAC
AGGCTCACAGTACTCCCTGGAC CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID
NO.: 54) LN01 variant 82 QVQLEESGPGLVQPWGTLS CAGGTGCAGCTGGAGGAATCTG
Variable Heavy (V.sub.H) LTCRVSGGSISSSSYYWAWI
GACCTGGACTGGTCCAGCCTTG (CDRH1, CDRH2 RQTPGRELQVIGTIYYSGTTY
GGGGACTCTGAGCCTGACCTGC and CDRH3 YNPSLRNRVTISLDKSVNVVS
CGGGTGTCAGGCGGGAGCATC underlined) LRLGSVSAADTAQYYCVRMP
AGCTCCTCTAGTTACTATTGGGC SHGFWSTSFSYWYFDLWGR TTGGATTAGGCAGACACCAGGC
GHFVAVSW CGCGAGCTGCAGGTCATCGGCA (SEQ ID NO. 23)
CTATCTACTATAGTGGGACCACA TACTATAACCCCTCACTGCGGA
ATAGAGTGACCATCTCCCTGGA CAAGTCTGTCAACGTGGTCTCT
CTGCGACTGGGATCAGTGAGCG CCGCTGATACCGCACAGTACTA
TTGCGTGCGGATGCCCAGCCAC GGCTTCTGGTCCACATCTTTTAG
TTACTGGTATTTCGACCTGTGG GGGCGGGGACATTTTGTGGCC GTCAGTTGG (SEQ ID NO.:
55) LN01 variant 82 DIQMTQSPSSLSASVGDKVTI GACATCCAGATGACCCAGTCTC
Variable Light (V.sub.L) TCRASQSVTKYLNWYQFKT CGTCCTCCCTGTCTGCCTCTGT
(CDRL1, CDRL2 and GQAPRILIYGTYTLLSGVSPR TGGAGACAAAGTCACCATCACC
CDRL3 underlined) FSGAGSGSLYTLTITNIQPED TGCCGGGCCAGTCAGAGTGTCA
FATYYCQQAHSTPWTFGQG CCAAATATTTAAATTGGTATCAG THVAAN
TTTAAGACCGGCCAAGCCCCAA (SEQ ID NO.: 24) GAATCCTCATCTATGGGACTTAT
ACTTTACTCAGTGGCGTCTCGC CTCGGTTCAGTGGCGCCGGATC
TGGTTCACTCTACACTCTGACCA TCACCAATATACAGCCTGAAGA
CTTCGCCACCTATTATTGTCAAC AGGCTCACAGTACTCCCTGGAC
CTTCGGCCAAGGAACCCACGTG GCGGCCAAC (SEQ ID NO : 56) LN01 variants 7
and GDSVSNWNYY (SEQ ID GGCGACAGCGTGTCCAACTGGA 48 Variable Heavy
NO.: 25) ACTACTAC (SEQ ID NO. 57) (V.sub.H) CDRH1 LN01 variant 8
GDSVSNDWYY (SEQ ID GGCGACAGCGTGTCCAACGACT Variable Heavy (V.sub.H)
NO.: 26) GGTACTAC (SEQ ID NO. 58) CDRH1 LN01 variant 41 GDSVSNFNYY
(SEQ ID GGGGACAGCGTCTCCAACTTTA Variable Heavy (V.sub.H) NO.: 27)
ATTACTAT(SEQ ID NO. 59) CDRH1 LN01 variant 42 GDSVSNYNYY (SEQ ID
GGGGACAGCGTCTCCAACTACA Variable Heavy (V.sub.H) NO.: 28) ATTACTAT
(SEQ ID NO. 60) CDRH1 LN01 variant 43 GDSVSNLNYY(SEQ ID
GGGGACAGCGTCTCCAACTTAA Variable Heavy (V.sub.H) NO.: 29) ATTACTAT
(SEQ ID NO. 61) CDRH1 LN01 variant 44 GDSVSNINYY (SEQ ID
GGGGACAGCGTCTCCAACATTA Variable Heavy (V.sub.H) NO.: 30) ATTACTAT
(SEQ ID NO. 62) CDRH1 LN01 variant 49 GDSVSNWWYY (SEQ ID
GGGGACAGCGTCTCCAACTGGT Variable Heavy (V.sub.H) NO.: 31) GGTACTAT
(SEQ ID NO. 63) CDRH1 LN01 variant 82 GSISSSSYY
GGGAGCATCAGCTCCTCTAGTT Variable Heavy (V.sub.H) (SEQ ID NO.: 32)
ACTAT (SEQ ID NO. 64) CDRH1 (germline sequence)
Thus, a nucleic acid encoding a binding agent of this disclosure
may comprise one or more SEQ ID NOS. 33-64 or GGGACTTAT, or a
derivative thereof that encodes any of SEQ ID NOS. 1-32 or GTY
(LN01 CDRL2) and/or a derivative thereof (e.g., any of SEQ ID NOS.
1-32 conservatively substituted as described in Table 2, encoded by
a nucleotide sequence determined using standard techniques, e.g.,
as described in Table 3, including but not limited to those
described in Table 4). Expression vectors comprising such nucleic
acid sequences are also contemplated by this disclosure. Where the
binding agents are antibodies, nucleotide sequences encoding the
variable regions thereof may also be isolated from the phage and/or
hybridoma cells expressing the same cloned into expression vectors.
Methods for producing such preparations are well-known in the
art.
[0046] Nucleic acid molecules encoding one or more HIV binding
agents may be contained within a viral and/or a non-viral vector.
In one embodiment, a DNA vector is utilized to deliver nucleic
acids encoding one or more HIV binding agents to the patient. In
doing so, various strategies may be utilized to improve the
efficiency of such mechanisms including, for example, the use of
self-replicating viral replicons (Caley, et al. 1999. Vaccine, 17:
3124-2135; Dubensky, et al. 2000. Mol. Med. 6: 723-732; Leitner, et
al. 2000. Cancer Res. 60: 51-55), codon optimization (Liu, et al.
2000. Mol. Ther., 1: 497-500; Dubensky, supra; Huang, et al. 2001.
J. Virol. 75: 4947-4951), in vivo electroporation (Widera, et al.
2000. J. Immunol. 164: 4635-3640), incorporation of nucleic acids
encoding co-stimulatory molecules, cytokines and/or chemokines
(Xiang, et al. 1995. Immunity, 2: 129-135; Kim, et al. 1998. Eur.
J. lmmunol., 28: 1089-1103; Iwasaki, et al. 1997. J. lmmunol. 158:
4591-3201; Sheerlinck, et al. 2001. Vaccine, 19: 2647-2656),
incorporation of stimulatory motifs such as CpG (Gurunathan, supra;
Leitner, supra), sequences for targeting of the endocytic or
ubiquitin-processing pathways (Thomson, et al. 1998. J. Virol. 72:
2246-2252; Velders, et al. 2001. J. lmmunol. 166: 5366-5373),
prime-boost regimens (Gurunathan, supra; Sullivan, et al. 2000.
Nature, 408: 605-609; Hanke, et al. 1998. Vaccine, 16: 439-445;
Amara, et al. 2001. Science, 292: 69-74), proteasome-sensitive
cleavage sites, and the use of mucosal delivery vectors such as
Salmonella (Darji, et al. 1997. Cell, 91: 765-775; Woo, et al.
2001. Vaccine, 19: 2945-2954). Other methods are known in the art,
some of which are described below. Various viral vectors that have
been successfully utilized for introducing a nucleic acid to a host
include retrovirus, adenovirus, adeno-associated virus (AAV),
herpes virus, and poxvirus, among others. The vectors may be
constructed using standard recombinant techniques widely available
to one skilled in the art. Such techniques may be found in common
molecular biology references such as Molecular Cloning: A
Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor
Laboratory Press), Gene Expression Technology (Methods in
Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press,
San Diego, Calif.), and PCR Protocols: A Guide to Methods and
Applications (Innis, et al. 1990. Academic Press, San Diego,
Calif.). "Non-viral" plasmid vectors may also be suitable in
certain embodiments. Preferred plasmid vectors are compatible with
bacterial, insect, and/or mammalian host cells. Such vectors
include, for example, PCR-ii, PCR3, and pcDNA3.1 (Invitrogen, San
Diego, Calif.), pBSii (Stratagene, La Jolla, Calif.), pet15
(Novagen, Madison, Wis.), pGEX (Pharmacia Biotech, Piscataway,
N.J.), pEGFp-n2 (Clontech, Palo Alto, Calif.), pETI (Bluebacii,
Invitrogen), pDSR-alpha (PCT pub. No. WO 90/14363) and pFASTBACdual
(Gibco-BRL, Grand island, N.Y.) as well as Bluescript.RTM. plasmid
derivatives (a high copy number COLe1-based phagemid, Stratagene
Cloning Systems, La Jolla, Calif.), PCR cloning plasmids designed
for cloning TAQ-amplified PCR products (e.g., TOPO.TM. TA
cloning.RTM. kit, PCR2.1.RTM. plasmid derivatives, Invitrogen,
Carlsbad, Calif.). Bacterial vectors may also be used. These
vectors include, for example, Shigella, Salmonella, Vibrio
cholerae, Lactobacillus, Bacille Calmette Guerin (BCG), and
Streptococcus (see for example, WO 88/6626; WO 90/0594; WO
91/13157; WO 92/1796; and WO 92/21376). Many other non-viral
plasmid expression vectors and systems are known in the art and may
be use. Other delivery techniques may also suffice including, for
example, DNA-ligand complexes, adenovirus-ligand-DNA complexes,
direct injection of DNA, CaPO.sub.4 precipitation, gene gun
techniques, electroporation, and colloidal dispersion systems.
Colloidal dispersion systems include macromolecule complexes,
nanocapsules, microspheres, beads, and lipid-based systems
including oil-in-water emulsions, micelles, mixed micelles, and
liposomes. The preferred colloidal system is a liposome, which are
artificial membrane vesicles useful as delivery vehicles in vitro
and in vivo. RNA, DNA and intact virions can be encapsulated within
the aqueous interior and be delivered to cells in a biologically
active form (Fraley, R., et al., 1981, Trends Biochem. Sci., 6:
77). The composition of the liposome is usually a combination of
phospholipids, particularly high-phase-transition-temperature
phospholipids, usually in combination with steroids, especially
cholesterol. Other phospholipids or other lipids may also be used.
The physical characteristics of liposomes depend on pH, ionic
strength, and the presence of divalent cations. Examples of lipids
useful in liposome production include phosphatidyl compounds, such
as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine,
phosphatidylethanolamine, sphingolipids, cerebrosides, and
gangliosides. Particularly useful are diacylphosphatidylglycerols,
where the lipid moiety contains from 14-18 carbon atoms,
particularly from 16-18 carbon atoms, and is saturated.
Illustrative phospholipids include egg phosphatidylcholine,
dipalmitoylphosphatidylcholine and
distearoylphosphatidylcholine.
[0047] A cultured cell comprising the vector is also provided. The
cultured cell may be a cultured cell transfected with the vector or
a progeny of the cell, wherein the cell expresses the immunogenic
polypeptide. Suitable cell lines are known to those of skill in the
art and are commercially available, for example, through the
American Type Culture Collection (ATCC). The transfected cells can
be used in a method of producing an immunogenic polypeptide. The
method comprises culturing a cell comprising the vector under
conditions that allow expression of the immunogenic polypeptide,
optionally under the control of an expression sequence. The
immunogenic polypeptide can be isolated from the cell or the
culture medium using standard protein purification methods.ln some
embodiments, the binding agents described herein may be conjugated
to active agents to target and inhibit the function of and /or
eliminate cell populations expressing HIV polypeptides and/or
harboring HIV (and/or another antigen in the case of binding agents
with multiple specificities). For instance, CD4.sup.+ T-cell
populations containing replication competent HIV may be targeted
and eliminated using binding agent / drug conjugates (e.g.,
antibody-drug conjugates (ADC)). Mono- and/or bi-specific candidate
binding agents may be conjugated with one or more types of drugs
(e.g., drugs damaging DNA, targeting microtubules). The binding
agents described herein and/ or derivatives thereof may also be
adjoined to and/or conjugated to functional agents for in vitro
and/or in vivo use. For instance, the binding agent may be adjoined
to and/or conjugated to functional moieties such as cytotoxic drugs
or toxins, and/or active fragments thereof such as diphtheria A
chain, exotoxin A chain, ricin A chain, abrin A chain, curcin,
crotin, phenomycin, enomycin, among others. Suitable functional
moieties may also include radiochemicals. Binding agents, such as
antibodies, may be adjoined to and/or conjugated to the one or more
functional agents using standard techniques in the art.
[0048] In some embodiments, this disclosure provides binding agents
with multiple specificities such that epitopes bound by LN01 (e.g.,
ITKWLWYIK (SEQ ID NO. 72) but not LASWVKYIQ (SEQ ID NO. 71) and/or
ITKWIKYIQ (SEQ ID NO. 73)) and at least one other secondary antigen
(e.g., a cell surface protein) may be bound by a single binding
agent. In some embodiments, the secondary antigen may be one
expressed by cells infected by an infectious agent. For instance,
an exemplary secondary antigen may be HIV Env antigen other than
gp41. Such binding agents may bind the secondary antigen and/or may
serve to neutralize the infectious agent as may be determined using
the assays described herein. Combinations of binding agents, such
as one or more described herein with another available to those of
ordinary skill in the art, are also contemplated herein. For
instance, in some embodiments, the combinations may be identified
to provide statistically significant differences from results
(e.g., neutralization assays) obtained using only one or more of
the binding agents and not others. In some embodiments,
combinations exhibit synergistic neutralization of HIV, for
example. In some embodiments, the combination may comprise a first
binding agent having the characteristics of LN01 (e.g., such as
IgG1 LN01) and/or comprising any one or more of SEQ ID NOS. 1-32
(and/or as described in Table 1), and/or derivatives thereof, and
any one or more of the antibodies described in any one or more of
U.S. Pat. Nos. 5,087,557; 5,298,419; 5,459,060; 5,693,752;
5,731,189; 5,753,503; 5,756,674; 5,777,074; 5,804,440; 5,831,034;
6,008,044; 7,774,887B2; U.S. Pat. Publications 2003/0118985A1,
2007/0292390A1, or 2014/0205612A1; WO 2002/032452A1 (e.g., binding
the gp41 epitopes ELDKWA, ELEKWA, ELNKWA, ELDEWA); EP0335134B1 US
176077 (e.g, a humanized version of the mouse mAbs described
therein); DE3932461A1 (mAb against the epitope
Arg-Ile-Leu-Ala-Val-Glu-Arg-Leu-Lys-Try-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-G-
ly-Cys-Ser); Evans, et al. J. Immunol. 140(3): 941-3 (1988);
Gorney, et al. Proc. Natl. Acad. Sci. USA, 86: 1624-28 (1989);
Teeuwsen, et al. (1990) AIDS Res. Hum. Retroviruses 6, 381-392;
Earl, et al. J. Virol. 71(4): 2674-2684 (1997); Jiang, et al. J.
Virol. 72(12): 10213-17 (1998); Zwick, et al. J. Virol. 75(22):
10892-10905 (2001); Eckert et al. PNAS USA, 98(20): 11187-11192
(2001); Louis, et al. J. Biol. Chem. 278(22): 20278-20285 (2003);
and/or Pietzsch, et al. J. Virol. 84(10): 5032-42 (2010); all of
which are incorporated herein in their entirety. For instance, any
of the binding agents described herein may be combined with (i.e.,
as a single composition, and/or used in conjunction with) one or
more the antibodies commonly known as 2F5, 4E10 and/or Z13e1,
and/or derivatives thereof, among others. The binding agents of
such compositions may be different entities such as two or more
different monoclonal antibodies or derivatives thereof, or may be
found on the same entity such as a bi-functional antibody (a single
antibody or derivative thereof comprising multiple binding
specificities). Such combinations as described herein may also be
combined with one or more other agents that may effect immune cell
function such as antibodies against CTLA-4, and the like. One of
ordindary skill in the art would recognize that many such
combinations may be suitable for use as descrbed herein.
[0049] As mentioned above, the HIV binding agents described herein
may be used to treat and/or prevent and/or ameliorate the symptoms
of infection by HIV. As is well-known in the art, HIV isolates are
now classified into discrete genetic subtypes. HIV-1 is known to
comprise at least ten subtypes (A1, A2, A3, A4, B, C, D, E, F1, F2,
G, H, J and K) (Taylor et al, NEJM, 359(18):1965-1966 (2008)).
HIV-2 is known to include at least five subtypes (A, B, C, D, and
E). Subtype B has been associated with the HIV epidemic in
homosexual men and intravenous drug users worldwide. Most HIV-1
immunogens, laboratory adapted isolates, reagents and mapped
epitopes belong to subtype B. In sub-Saharan Africa, India and
China, areas where the incidence of new HIV infections is high,
HIV-1 subtype B accounts for only a small minority of infections,
and subtype HIV-1 C appears to be the most common infecting
subtype. Any of these types of isolates may be addressed using the
binding agents described herein. One or more binding agents may
also be administered with or in conjunction with one or more agents
used to prevent, treat and/or ameliorate HIV such as for example, a
protease inhibitor, an HIV entry inhibitor, a reverse transcriptase
inhibitor, and/or an anti- retroviral nucleoside analog. Suitable
compounds include, for example, Agenerase (amprenavir), Combivir
(Retrovir/Epivir), Crixivan (indinavir), Emtriva (emtricitabine),
Epivir (3tc / lamivudine), Epzicom, Fortovase/Invirase
(saquinavir), Fuzeon (enfuvirtide), Hivid (ddc/zalcitabine),
Kaletra (lopinavir), Lexiva (Fosamprenavir), Norvir (ritonavir),
Rescriptor (delavirdine), Retrovir/AZT (zidovudine), Reyatax
(atazanavir, BMS-232632), Sustiva (efavirenz), Trizivir
(abacavir/zidovudine/lamivudine), Truvada (Emtricitabine/Tenofovir
DF), Videx (ddl/didanosine), Videx EC (ddl, didanosine), Viracept
(nevirapine), Viread (tenofovir disoproxil fumarate), Zerit
(d4T/stavudine), and Ziagen (abacavir) may be utilized. Other
suitable agents are known to those of skill in the art and may be
suitable for use as described herein. Such agents may either be
used prior to, during, or after administration of the binding
agents and/or use of the methods described herein.
[0050] The skilled artisan has many suitable techniques for using
the binding agents (e.g., antibodies) described herein to identify
biological samples containing proteins that bind thereto. For
instance, antibodies may be utilized to isolate HIV or cells
containing HIV and/or expressing HIV antigens using, for example,
immunoprecipitation or other capture-type assay. This well-known
technique is performed by attaching the antibody to a solid support
or chromatographic material (e.g., a bead coated with Protein A,
Protein G and/or Protein L). The bound antibody is then introduced
into a solution either containing or believed to contain HIV
antigens (e.g., an HIV-infected cell). The HIV antigen(s) may then
bind to the antibody and non-binding materials are washed away
under conditions in which the HIV antigen(s) remains bound to the
antibody. The bound protein may then be separated from the antibody
and analyzed as desired. Similar methods for isolating a protein
using an antibody are well-known in the art. The binding agents
(e.g., antibodies) may also be utilized to detect HIV or HIV
antigens within a biological sample. For instance, the antibodies
may be used in assays such as, for example, flow cytometric
analysis, ELISA, immunoblotting (e.g., western blot), in situ
detection, immunocytochemistry, and/or immunhistochemistry. Methods
of carrying out such assays are well-known in the art. In some
embodiments, the binding agents may be adjoined to and/or
conjugated to one or more detectable labels. For instance, suitable
detectable labels may include, for instance, fluorosceins (e.g.,
DyLight, Cy3, Cy5, FITC, HiLyte Fluor 555, HiLyte Fluor 647;
5-carboxy-2,7-dichlorofluorescein; 5-Carboxyfluorescein (5-FAM);
5-HAT (Hydroxy Tryptamine); 5-Hydroxy Tryptamine (HAT); 6-JOE;
6-carboxyfluorescein (6-FAM); FITC;
6-carboxy-1,4-dichloro-2',7'-dichlorofluorescein (TET);
6-carboxy-1,4-dichloro-2', 4', 5', 7'-tetrachlorofluorescein (HEX);
6-carboxy-4', 5'-dichloro-2', 7'-dimethoxyfluorescein (JOE); Alexa
fluors (e.g., 350, 405, 430, 488, 500, 514, 532, 546, 555, 568,
594, 610, 633, 635, 647, 660, 680, 700, 750); BODIPY fluorophores
(e.g., 492/515, 493/503, 500/510, 505/515, 530/550, 542/563,
558/568, 564/570, 576/589, 581/591, 630/650-X, 650/665-X, 665/676,
FL, FL ATP, FI-Ceramide, R6G SE, TMR, TMR-X conjugate, TMR-X, SE,
TR, TR ATP, TR-X SE)), rhodamines (e.g., 110, 123, B, B 200, BB,
BG, B extra, 5-carboxytetramethylrhodamine (5-TAMRA), 5 GLD,
6-Carboxyrhodamine 6G, Lissamine, Lissamine Rhodamine B,
Phallicidine, Phalloidine, Red, Rhod-2, ROX
(6-carboxy-X-rhodamine), 5-ROX (carboxy-X-rhodamine),
Sulphorhodamine B can C, Sulphorhodamine G Extra, TAMRA
(6-carboxytetramethyl-rhodamine), Tetramethylrhodamine (TRITC),
WT), Texas Red, and/or Texas Red-X. Other detectable labels known
in the art may also be suitable for use. Binding agents, such as
antibodies, may be adjoined to and/or conjugated to the one or more
detectable labels using standard techniques in the art.
[0051] The binding agents described herein may be also be used to
determine the presence of a disease state in a patient, to predict
prognosis, or to determine the effectiveness of a chemotherapeutic
or other treatment regimen. Expression profile assays, performed as
described herein or as is otherwise known in the art, may be used
to determine the relative level of expression of HIV in a cell, for
instance. The level of expression may then be correlated with base
(e.g., control) levels to determine whether a particular disease is
present within the patient, the patient's prognosis, or whether a
particular treatment regimen is effective. For example, if the
patient is being treated with a particular anti-infective regimen,
an increased or decreased level of expression of HIV in the
patient's tissues (e.g., in plasma) may indicate the regimen is
worsening or improving the load of HIV in that host. The increase
or decrease in expression may indicate the regimen is having or not
having the desired effect and another therapeutic modality may
therefore be selected.
[0052] It is also possible to use the binding agents described
herein as reagents in drug screening assays to test, for example,
new drug candidates. The reagents may be used to ascertain the
effect of a drug candidate on the expression of the immunogenic
target in a cell line, or a cell or tissue of a patient. The
expression profiling technique may be combined with high throughput
screening techniques to allow rapid identification of useful
compounds and monitor the effectiveness of treatment with a drug
candidate (see, for example, Zlokarnik, et al., Science 279, 84-8
(1998)). Drug candidates may be chemical compounds, nucleic acids,
proteins, antibodies, or derivatives therefrom, whether naturally
occurring or synthetically derived. Drug candidates thus identified
may be utilized, among other uses, as pharmaceutical compositions
for administration to patients or for use in further screening
assays.
[0053] In some embodiments, the binding agents are in purified
form. A "purified" binding agent (e.g., antibody) may be one that
is separated from at least about 50% of the proteins and/or other
components with which it is initially found (e.g., as part of a
hybridoma supernatant or ascites preparation in the case of a
monoclonal antibody). A purified binding agent (e.g., antibody) may
be one that is separated from at least about 50%, 60%, 75%, 90%, or
95% of the proteins and/or other components with which it is
initially found.
[0054] The polypeptides and nucleic acids described herein may also
be combined with one or more pharmaceutically acceptable carriers
prior to administration to a host. A pharmaceutically acceptable
carrier is a material that is not biologically or otherwise
undesirable, e.g., the material may be administered to a subject,
without causing any undesirable biological effects or interacting
in a deleterious manner with any of the other components of the
pharmaceutical composition in which it is contained. The carrier
would naturally be selected to minimize any degradation of the
active ingredient and to minimize any adverse side effects in the
subject, as would be well known to one of skill in the art.
Suitable pharmaceutical carriers and their formulations are
described in, for example, Remington's: The Science and Practice of
Pharmacy, 21.sup.st Edition, David B. Troy, ed., Lippicott Williams
& Wilkins (2005). Typically, an appropriate amount of a
pharmaceutically-acceptable salt is used in the formulation to
render the formulation isotonic. Examples of the
pharmaceutically-acceptable carriers include, but are not limited
to, sterile water, saline, buffered solutions like Ringer's
solution, and dextrose solution. The pH of the solution is
generally from about 5 to about 8 or from about 7 to about 7.5.
Other carriers include sustained-release preparations such as
semipermeable matrices of solid hydrophobic polymers containing
polypeptides or fragments thereof. Matrices may be in the form of
shaped articles, e.g., films, liposomes or microparticles. It will
be apparent to those persons skilled in the art that certain
carriers may be more preferable depending upon, for instance, the
route of administration and concentration of composition being
administered. Carriers are those suitable for administration of
polypeptides and/or fragments thereof to humans or other subjects.
Pharmaceutical compositions may also include carriers, thickeners,
diluents, buffers, preservatives, surface active agents, adjuvants,
immunostimulants, in addition to the immunogenic polypeptide.
Pharmaceutical compositions may also include one or more active
ingredients such as antimicrobial agents, antiinflammatory agents
and anesthetics. The pharmaceutical composition may be administered
orally, parentally, by inhalation spray, rectally, intranodally, or
topically in dosage unit formulations containing conventional
pharmaceutically acceptable carriers, adjuvants, and vehicles. The
term "pharmaceutically acceptable carrier" or "physiologically
acceptable carrier" as used herein refers to one or more
formulation materials suitable for accomplishing or enhancing the
delivery of a nucleic acid, polypeptide, or peptide as a
pharmaceutical composition. A "pharmaceutical composition" is a
composition comprising a therapeutically effective amount of a
nucleic acid or polypeptide. The terms "effective amount" and
"therapeutically effective amount" each refer to the amount of a
binding agent, nucleic acid or the like used to observe the desired
therapeutic effect (e.g., eliminating HIV).
[0055] Methods for treating one or more disease conditions (e.g.,
HIV or cancer) in a mammalian host comprising administering to the
mammal at least one or more effective doses of one or more binding
agents (and/or derivative(s) thereof) described herein are also
provided. In some embodiments, the binding agent is a monoclonal
antibody or fragment or derivative thereof comprising one or more
of SEQ ID NOS. 1-32 and/or shown in Table 1. The one or more
binding agents may be administered in a dosage amount of about 1 to
about 50 mg/kg, about 1 to about 30 mg/kg, or about 5 to about 30
mg/kg (e.g., about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30, 35, or 40 mg/kg). In certain embodiments, the one or more
binding agents may be administered to the mammal (e.g.,
intradermally, intravenously, orally, rectally) at about 10 mg / kg
one or more times. When multiple doses are administered, the doses
may comprise about the same or different amount of binding agent in
each dose. The doses may also be separated in time from one another
by the same or different intervals. For instance, the doses may be
separated by about any of 6, 12, 24, 36, 48, 60, 72, 84, or 96
hours, one week, two weeks, three weeks, one month, two months,
three months, four months, five months, six months, seven months,
eight months, nine months, 10 months, 11 months, 12 months, 1.5
years, 2 years, 3 years, 4 years, 5 years, or any time period
before, after, and/or between any of these time periods. In some
embodiments, the binding agents may be administered in conjunction
with other agents (e.g., anti-infective agents and/or
chemotherapeutic agent). Such other agents may be administered
about simultaneously with the binding agents, or at a different
time and/or frequency. Other embodiments of such methods may also
be appropriate as could be readily determined by one of ordinary
skill in the art.
[0056] To assist the skilled artisan in using the binding agents
such as antibodies described herein, the same may be provided in
kit format. A kit including one or more of such binding agents and
optionally other components necessary for using the same to detect
cells expressing HIV is also provided. The binding agents of the
kit may be provided in any suitable form, including frozen,
lyophilized, or in a pharmaceutically acceptable buffer such as TBS
or PBS. The kit may also include other reagents required for
utilization of the binding agents in vitro or in vivo such as
buffers (e.g., TBS, PBS), blocking agents (solutions including
nonfat dry milk, normal sera, Tween-20 Detergent, BSA, or casein),
and/or detection reagents (e.g., goat anti-mouse IgG biotin,
streptavidin-HRP conjugates, allophycocyanin, B-phycoerythrin,
R-phycoerythrin, peroxidase, detectable labels, and other labels
and/or staining kits (e.g., ABC Staining Kit, Pierce)). The kits
may also include other reagents and/or instructions for using the
antibodies in commonly utilized assays described above such as, for
example, flow cytometric analysis, ELISA, immunoblotting (e.g.,
western blot), in situ detection, immunocytochemistry,
immunhistochemistry. In one embodiment, the kit provides a binding
agent in purified form. In another embodiment, the binding agent
may be provided in biotinylated form either alone or along with an
avidin-conjugated detection reagent (e.g., antibody). In another
embodiment, the kit includes a binding agents comprising one or
more detectable labels that may be used to directly detect HIV.
Buffers and the like required for using any of these systems are
well-known in the art and/or may be prepared by the end-user or
provided as a component of the kit. The kit may also include a
solid support containing positive- and negative-control protein
and/or tissue samples. For example, kits for performing spotting or
western blot-type assays may include control cell or tissue lysates
for use in SDS-PAGE or nylon or other membranes containing
pre-fixed control samples with additional space for experimental
samples. Kits for visualization of HIV in cells on slides may
include pre-formatted slides containing control cell or tissue
samples with additional space for experimental samples. Other
embodiments of kits are also contemplated herein as would be
understood by those of ordinary skill in the art.
[0057] Thus, this disclosure provides binding agents such as the
LN01 antibody with specificity for HIV. In some embodiments, the
binding agent is a polypeptide comprising at least one amino acid
sequence selected from the group consisting of SEQ ID NOS. 1-32
and/or shown in Table
[0058] 1. In some embodiments, the binding agent is a polypeptide
comprising one or more combinations of SEQ ID NOS. 1-32. In some
embodiments, the binding agent is an antibody. In some embodiments,
the binding agent is a polypeptide such as an antibody comprising a
heavy chain CDR amino acid sequence selected from the group
consisting of SEQ ID NOS. 1-3. In some embodiments, the binding
agent is a polypeptide such as an antibody comprising a light chain
CDR amino acid sequence selected from the group consisting of SEQ
ID NOS. 4-7. In some embodiments, the binding agent is a
polypeptide such as an antibody comprising a V.sub.H amino acid
sequence of SEQ ID NO. 7 (LN01), SEQ ID NO. 9 (LN01 variant 7), SEQ
ID NO. 11 (LN01 variant 8), SEQ ID NO. 13 (LN01 variant 38), SEQ ID
NO. 15 (LN01 variant 41), SEQ ID NO. 17 (LN01 variant 42), SEQ ID
NO. 19 (LN01 variant 48), SEQ ID NO. 21 (LN01 variant 49), or SEQ
ID NO. 23 (LN01 variant 82). In some embodiments, the binding agent
is a polypeptide such as an antibody comprising a V.sub.L amino
acid sequence of SEQ ID NO. 8 (LN01), SEQ ID NO. 10 (LN01 variant
7), SEQ ID NO. 12 (LN01 variant 8), SEQ ID NO. 14 (LN01 variant
38), SEQ ID NO. 16 (LN01 variant 41), SEQ ID NO. 18 (LN01 variant
42), SEQ ID NO. 20 (LN01 variant 48), SEQ ID NO. 22 (LN01 variant
49), or SEQ ID NO. 28 (LN01 variant 24). In some embodiments, the
binding agent comprises the combinations of CDRs (SEQ ID NOS. 1-6
or GNT (LN01 CDRL1)) and/or variable regions (SEQ ID NOS. 7 and 8;
SEQ NOS. 9 and 10; SEQ NOS. 11 and 12; SEQ NOS. 13 and 14; SEQ NOS.
15 and 16; SEQ NOS. 17 and 18; SEQ NOS. 19 and 20; SEQ NOS. 21 and
22; or, SEQ ID NOS. 23 and 24; or a conservatively substituted
variant thereof) shown in Table 1.
[0059] In some embodiments, the binding agents have specificity for
an epitope comprising amino acid residues L679, W680 and K683 of
SEQ ID NO. 68 and/or amino acid residues L168, W169 and K172 of SEQ
ID NO. 69. In some embodiments, the binding agent exhibits the
capacity to bind to and/or neutralize HIV expressing amino acid
sequence ITKWLWYIK (SEQ ID NO. 66). In some embodiments, the
binding agent exhibits the capacity to bind to and/or neutralize
HIV expressing amino acid sequence ITKWLWYIK (SEQ ID NO. 66) but
not LASWVKYIQ (SEQ ID NO. 65) and/or ITKWIKYIQ (SEQ ID NO. 67). In
some embodiments, a binding agent of this disclosure may comprise
any one or more of these binding specificities along with the
neutralization characteristics described above (i.e.,
neutralization of HIV-1 pseudoviruses BJOX (CRF07_BC), CE1176,
TRO.11 (B), X1632 (G), CH119 (CRF07_BC), CNE55 (CRF01_AE), 25710
(C), CD0217(C) but not of the control virus SVA-MLV at a
concentration is from 10.sup.2-10.sup.0 ug/ml, or between
10.sup.0-10.sup.1 ug/ml, to at least about 50%, and/or the ability
to the neutralize a majority of the 118 HIV-1 pseudoviruses listed
in FIG. 4 at an IC.sub.50 of less than 25). In some embodiments,
nucleic acids encoding such binding agents are also provided as in
Table 4.
[0060] In some embodiments, the binding agent is derived from or
related to (e.g., by sequence or derivation) a human antibody,
human IgG, human IgG1, human IgG2, human IgG2a, human IgG2b, human
IgG3, human IgG4, human IgM, human IgA, human IgA1, human IgA2,
human IgD, human IgE, canine antibody, canine IgGA, canine IgGB,
canine IgGC, canine IgGD, chicken antibody, chicken IgA, chicken
IgD, chicken IgE, chicken IgG, chicken IgM, chicken IgY, goat
antibody, goat IgG, mouse antibody, mouse IgG, pig antibody, and/or
rat antibody, and/or a derivative thereof. In some embodiments, the
derivative may be selected from the group consisting of an
F.sub.ab, F.sub.ab2, Fab' single chain antibody, F.sub.v, single
chain, mono-specific antibody, bispecific antibody, trimeric
antibody, multi-specific antibody, multivalent antibody, chimeric
antibody, canine-human chimeric antibody, canine-mouse chimeric
antibody, antibody comprising a canine Fc, humanized antibody,
human antibody, caninized antibody, CDR-grafted antibody, shark
antibody, nanobody, and/or canelid antibody. In some embodiments,
the binding agent comprises at least a least a first and second
specificity, the first being against HIV gp41 and the second being
against a different antigen (e.g., an antigen of an infectious
agent such as HIV (e.g., env) and/or a tumor antigen). In some
embodiments, the binding agent and/or derivative thereof may
comprise a detectable label fixably attached thereto. In some
embodiments, the binding agent of any one and/or derivative thereof
comprises an effector moiety (e.g., a cytotoxic drug, toxin,
diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain,
curcin, crotin, phenomycin, enomycin, and radiochemical) fixably
attached thereto. In some embodiments, polynucleotides encoding one
or more binding agents are also provided (e.g., as an expression
vector). Host cells comprising and/or expressing the polypeptide
products of such polynucleotides are also provided. In some
embodiments, compositions comprising at least one binding agent or
derivative; at least one isolated polynucleotide; at least one
expression vector; and/or, at least one host cell; or a combination
thereof; and, a pharmaceutically acceptable carrier are also
provided.
[0061] This disclosure also provides methods for detecting HIV on a
cell, the method comprising contacting a test biological sample
with a binding agent or derivative described herein and detecting
the binding agent bound to the biological sample or components
thereof. Such methods may be an in vivo method or an in vitro
method. In some embodiments, the method may comprise comparing the
amount of binding to the test biological sample or components
thereof to the amount of binding to a control biological sample or
components thereof, wherein increased binding to the test
biological sample or components thereof relative to the control
biological sample or components thereof indicates the presence of a
cell expressing HIV polypeptides in the test biological sample
(e.g., mammalian blood). In some embodiments, a kit for detecting
the expression of HIV in or on a cell, the kit comprising a binding
agent or derivative thereof and instructions for use. In some
embodiments, the binding agent and/or derivative thereof is in
lyophilized form. In some embodiments, this disclosure provides
methods for treating, preventing and/or ameliorating an infectious
disease, cancer and/or autoimmunity in a mammal comprising
administering to the mammal at least one effective dose of a
pharmaceutical composition comprising a binding agent or derivative
thereof. In some embodiments, the infectious disease is human
immunodeficiency virus (HIV). In some embodiments, multiple doses
are administered to the animal. In some embodiments, the binding
agent and/or derivative thereof may be administered in a dosage
amount of about 1 to 50 mg/kg.
[0062] The terms "about", "approximately", and the like, when
preceding a list of numerical values or range, refer to each
individual value in the list or range independently as if each
individual value in the list or range was immediately preceded by
that term. The terms mean that the values to which the same refer
are exactly, close to, or similar thereto.
[0063] As used herein, a subject or a host is meant to be an
individual. The subject can include domesticated animals, such as
cats and dogs, livestock (e.g., cattle, horses, pigs, sheep, and
goats), laboratory animals (e.g., mice, rabbits, rats, guinea pigs)
and birds. In one aspect, the subject is a mammal such as a primate
or a human.
[0064] Optional or optionally means that the subsequently described
event or circumstance can or cannot occur, and that the description
includes instances where the event or circumstance occurs and
instances where it does not. For example, the phrase optionally the
composition can comprise a combination means that the composition
may comprise a combination of different molecules or may not
include a combination such that the description includes both the
combination and the absence of the combination (i.e., individual
members of the combination).
[0065] Ranges may be expressed herein as from about one particular
value, and/or to about another particular value. When such a range
is expressed, another aspect includes from the one particular value
and/or to the other particular value. Similarly, when values are
expressed as approximations, by use of the antecedent about or
approximately, it will be understood that the particular value
forms another aspect. It will be further understood that the
endpoints of each of the ranges are significant both in relation to
the other endpoint, and independently of the other endpoint. Ranges
(e.g., 90-100%) are meant to include the range per se as well as
each independent value within the range as if each value was
individually listed.
[0066] The term "combined" or "in combination" or "in conjunction"
may refer to a physical combination of agents that are administered
together or the use of two or more agents in a regimen (e.g.,
administered separately, physically and/or in time) for treating,
preventing and/or ameliorating a particular disease.
[0067] When the terms treat, prevent, and/or ameliorate or
derivatives thereof are used herein in connection with a given
treatment for a given condition (e.g., preventing cancer infection
by HIV), it is meant to convey that the treated patient either does
not develop a clinically observable level of the condition at all,
or develops it more slowly and/or to a lesser degree than he/she
would have absent the treatment. These terms are not limited solely
to a situation in which the patient experiences no aspect of the
condition whatsoever. For example, a treatment will be said to have
prevented the condition if it is given during exposure of a patient
to a stimulus that would have been expected to produce a given
manifestation of the condition, and results in the patient's
experiencing fewer and/or milder symptoms of the condition than
otherwise expected. For instance, a treatment can "prevent"
infection by resulting in the patient's displaying only mild overt
symptoms of the infection; it does not imply that there must have
been no penetration of any cell by the infecting microorganism.
[0068] Similarly, reduce, reducing, and reduction as used herein in
connection with prevention, treatment and/or amelioration of a
given condition by a particular treatment typically refers to a
subject developing an infection more slowly or to a lesser degree
as compared to a control or basal level of developing an infection
in the absence of a treatment (e.g., administration of one or more
HIV binding agents). A reduction in the risk of infection may
result in the patient's displaying only mild overt symptoms of the
infection or delayed symptoms of infection; it does not imply that
there must have been no penetration of any cell by the infecting
microorganism.
[0069] All references cited within this disclosure are hereby
incorporated by reference in their entirety. Certain embodiments
are further described in the following examples. These embodiments
are provided as examples only and are not intended to limit the
scope of the claims in any way.
EXAMPLES
Example 1
Lymph Node Donors
[0070] Selection of HIV-1 lymph node donors for the isolation of
broadly neutralizing antibodies. In order to isolate broadly
neutralizing antibodies capable to broadly neutralize multi-clade
HIV-1 isolates 70 plasma samples from chronically infected patients
naive to antiretroviral therapy were screened for the presence of
high titers of antibodies able to neutralize a panel of nine (9)
HIV-1 pseudoviruses from the Global Panel of HIV-1 reference
strains (DeCamp, A. et al. Global panel of HIV-1 Env reference
strains for standardized assessments of vaccine-elicited
neutralizing antibodies. J Virol 88, 2489-2507 (2014)). This
analysis resulted in the identificiation of seven (7) patients
(FIG. 1) as lymph node donors for the subsequent isolation and
characterization of potent broadly neutralizing antibodies. In
particular, donor SA003 was selected for the presence high level of
antibodies found to neutralize eight (8) out of nine (9) isolates
tested (and for the lack of background activity against the
negative control MLV pseudovirus). Of note, SA003 donor is an Elite
Controller with viremia <50 HIV RNA copies per ml of plasma
(infected with clade B HIV-1).
[0071] Example 2
Isolation and Characterization of a Potent HIV-1 Broadly
Neutralizing Antibody
[0072] Germinal center and Memory IgG B cells from donor SA003 were
sorted separately according to IgG (i.e. IgA and IgM negative
cells), CD19 and CD38 expression (germinal center B cells are CD38
positive) (FIG. 2) and interrogated for the production of HIV-1
neutralizing antibodies. In particular, highly pure IgG memory B
cells and IgG germinal cells were seeded in separate plates as
single cell micro-cultures on human feeder cells in the presence of
Epstein-Barr Virus (EBV) (which also stimulate polyclonally memory
B cells) and a cocktail composed TLR9 agonist CpG-2006, IL-2 (1000
IU/ml), IL-6 (10 ng/ml), IL-21 (10 ng/ml), and anti-BCR goat
antibodies (BCR triggerring). Supernatants from day 14 cultures
were then tested in a primary screening using a 384-well based
HIV-1 pseudoviruses neutralization assay (using in parallel two
strains, CE1176 and BJOX2000, representative of clade C and CRF07).
Neutralization assays were undertaken on TZM-bl cells. In a
384-well plate, HIV-1 pseudoviruses that resulted in an output of
50-100.times.10.sup.4 relative light units (RLU) were incubated
with B cell culture supernatants for 1 h at 37% (5% CO2) before the
addition of 3000 TZM-bl cells. These were incubated for a further
72 h, after which supernatant was removed and 15 .mu.l Steadylite
reagent (Perkin Elmer) was added. Luciferase activity was detected
5 min later by reading the plates on a Synergy microplate
luminometer (BioTek). The supernatants derived from two cultures of
germinal center B cells were found able to cross-neutralize both
CE1176 and BJOX2000 strains. The supernatants from these two
cultures were further harvested and tested for their ability to
neutralize four (4) pseudoviruses (CE1176, BJOX2000, X1632 and
25710). Of note, one of the two supernatants neutralized all four
pseudoviruses. The antibody derived from the neutralizing culture
was characterized by determining the amino acid and nucleotide
sequences of its variable regions (Tables 1 and 5) and the
complementarity determining regions (CDRs) therein and termed
"LN01". Accordingly, the binding agent termed "LN01" is an
IgG3-type fully human monoclonal antibody having the CDR, VH and VL
sequences as shown above in Tables 1 and 2. This antibody was
derived from IGHV4-39*07 and IGKV1-39*01 germline genes, and was
highly somatically mutated in variable genes of both heavy chain
(28%) and kappa light chain (27%) compared to germ line. The LN01
antibody also possessed a long heavy-chain
complementarity-determining 3 region (CDR H3) loop composed of 20
amino acids. The LN01 VH and VL genes were cloned into IgG1
expression vectors, and the recombinant IgG1 LN01 antibody was
produced by transfecting Expi293F cells. The full-length IgG1 LN01
antibody was then purified using a recombinant protein-A column
(GE-Healthcare).
[0073] The recombinantly produced IgG1 LN01 antibody was then
tested against the Global Panel of nine (9) HIV-1 reference
pseudoviruses on TZM-bl cells. Strikingly, IgG1 LN01 antibody
neutralized eight (8) out of nine (9) HIV-1 pseudoviruses with
IC.sub.50 values ranging from 0.03 to 1.6 .mu.g/ml (FIG. 3) and did
not neutralize the negative control MLV pseudovirus. IgG1 LN01
antibody was subsequently tested on an extended panel of 118 HIV-1
pseudoviruses including clade A, clade B, clade C, clade D, clade
G, circulating recombinant forms CRF10_CD, CRF01_AE, CRF02_AG and
CRF07_BC and non-circulating recombinants AC and ACD strains. IgG1
LN01 antibody broadly neutralized 109 viruses out of 118 with IC50
below 25 .mu.g/ml, i.e. the 92% of the tested viruses, with a
median IC50 of 1.1 .mu.g/ml (FIGS. 4 and 5). The analysis of the
viruses neutralized indicated that LN01 neutralizing activity is
not clade-dependent.
[0074] Example 3
Effect of Fc Receptors on LN01 Neutralizing Activity
[0075] IgG1 LN01 antibody was tested against the Global Panel of
nine (9) HIV-1 reference pseudoviruses on parental TZM-bl cells and
TZM-bl cells expressing Fc-gamma receptor I (CD64) (Perez, L. G.,
Costa, M. R., Todd, C. A., Haynes, B. F. & Montefiori, D. C.
Utilization of immunoglobulin G Fc receptors by human
immunodeficiency virus type 1: a specific role for antibodies
against the membrane-proximal external region of gp41. J Virol 83,
7397-7410 (2009)). Of note, the neutralizing activity of IgG1 LN01
antibody was enhanced 100-fold in TZM-bl cells expressing Fc-gamma
receptor I (FIG. 6). In addition, IgG1 LN01 antibody showed potent
neutralization against the strain CE0217 using TZM-bl cells
expressing Fc-gamma receptor I that was not neutralized by IgG1
LN01 antibody on TZM-bl cells (IC.sub.50>25 .mu.g/ml)). These
results suggest that by prepositioning of IgG1 LN01 antibody at the
cell surface, Fc-gamma receptors might give Abs a kinetic advantage
for virus inhibition. This kinetic advantage could be unique to
antibodies, whose epitopes are thought to be difficult to access or
exposed for only a short time on intermediate conformations of the
Env protein during an early stage of fusion. Another mechanism by
which Fc-gamma receptors could potentially facilitate HIV-1
neutralization is phagocytosis. HeLa cells, from which the TZM-bl
cell line was constructed, are known to exhibit properties of
nonprofessional phagocytes. Thus, it is possible that TZM-bl cells
were converted to professional phagocytic cells by introducing
Fc-gamma receptor on their surface. Any Fc-gamma-receptor-mediated
antiviral effects on HIV-1 neutralizing antibodies, whether by
entry inhibition or phagocytosis, might be beneficial to several
cell types in vaccine setting. Fc-gamma receptors are rarely
expressed on CD4+ lymphocytes, several additional HIV-1-susceptible
cell types express multiple Fc-gamma receptors and are involved in
sexual transmission and the early establishment of long-lived viral
reservoirs. In particular, macrophages are among the first
infection-susceptible cells that the virus encounters after mucosal
exposure, and they are thought to serve as a long-lived virus
reservoir in chronic infection. Macrophages are well known to
express multiple Fc-gamma receptors as well as certain subsets of
monocytes and dendritic cells. It is also important to mention that
Fc-gamma receptors play a role in regulating adaptive immunity and
peripheral tolerance, by facilitating antigen uptake, antigen
presentation, cell activation and B cell tolerance.
Example 4
LN01 Specificity
[0076] In order to better define the specificity of IgG1 LN01
antibody we used a panel of HIV-2/HIV-1 chimeric pseudoviruses
containing various segments of the HIV-1 MPER into the parental
HIV-2/7312A. IgG1 LN01 antibody did not neutralize the parental
HIV-2 7312A strain. Of note, IgG1 LN01 antibody was found to
potently neutralize the chimeric virus 7312A.C4 in which only 6
residues from HIV-1 were replaced in the HIV-2 MPER region
(LASWVKYIQ (SEQ ID NO. 65) was replaced into ITKWLWYIK (SEQ ID NO.
66)), but not the chimeric virus 7312A.C6 in which only 3 residues
in the same region were replaced (LASWVKYIQ (SEQ ID NO. 65) was
replaced into ITKWIKYIQ (SEQ ID NO. 67)) (FIG. 7). A similar
finding was obtained with the chimeric virus 7312A.C1C where the
same 6 mutations of 7312A.C4 were combined with additional 7
mutations in the N-terminal region. These results indicate that
residues in the C terminal region of the gp41 MPER (L679, W680 and
K683) are involved in IgG1 LN01 antibody binding.
[0077] In order to better define the specificity of LN01 we used a
peptide microarray formed by 1423 15-mer peptides, overlapping by
12 amino acids, that cover the full length of the consensus HIV-1
Env gp160 sequences for clades A, B, C, D, group M, CRF01_AE and
CRF02_AG. The peptides were printed onto 3D-Epoxy glass slides and
were analyzed with a GenePix 4000B scanner (Tomaras, G. D. et al.
Polyclonal B cell responses to conserved neutralization epitopes in
a subset of HIV-1-infected individuals. J Virol 85, 11502-11519
(2011)). LN01 was tested at 20 .mu.g/ml in parallel with a control
antibody called 7B2 (that is specific for the immunodominant region
of gp41) for binding to the peptide microarray. The binding of LN01
and 7B2 was detected by incubation with DyLight 649-labeled goat
anti-human IgG. Fluorescence intensity was measured using a GenePix
4000B scanner and was analyzed with GenePix software (FIG. 8). Of
note, IgG1 LN01 antibody did not clearly react with any of the
peptides in this library, while 7B2 strongly reacted with 190-195
peptides that spanned the gp41 immunodominant region. These results
indicate that IgG1 LN01 antibody does not recognize a linear
epitope in HIV-1 Env.
[0078] IgG1 LN01 antibody was also tested for binding to soluble,
cleaved SOSIP.664 gp140 trimers based on the subtype A
transmitted/founder strain, BG505. These trimers are highly stable,
homogenous and closely resemble native virus spikes when visualized
by negative stain electron microscopy (EM) (Sanders, R. W. et al. A
next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664
gp140, expresses multiple epitopes for broadly neutralizing but not
non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013)). All
broadly neutralizing antibodies against multiple neutralizing
epitopes on HIV-1 Env were highly reactive with the BG505 SOSIP.664
gp140 trimers, including quaternary epitopes antibodies (CH01, PG9,
PG16 and PGT145). Conversely, non-NAbs to the CD4-binding site,
CD4-induced epitopes or gp41 ectodomain did not react with the
trimers, even when their epitopes were present on simpler forms of
Env (e.g. gp120 monomers or dissociated gp41 subunits). The MPER
was also deleted to improve trimer solubility and reduce aggregate
formation. IgG1 LN01 antibody, PGT145 (V1-V2 glycan specific),
PGT151 (binding to a site at the interface between gp120 and gp41)
and 17b (binding to a CD4 binding induced site) antibodies were
tested for binding to BG505 SOSIP.664 gp140 trimers in the presence
or absence of soluble CD4 (sCD4) by surface plasmon resonance
(SPR). PGT145 and PGT151 antibodies reacted strongly to BG505
SOSIP.664 gp140 trimers in the presence and absence of sCD4; 17b
reacted to BG505 SOSIP.664 gp140 trimers only in the presence of
sCD4. LN01 did not react with BG505 SOSIP.664 gp140 trimers neither
in the presence nor in the absence of sCD4 (FIG. 9).
[0079] IgG1 LN01 antibody, in parallel with MPER-specific 10E8
antibody (Huang, J. et al. Broad and potent neutralization of HIV-1
by a gp41-specific human antibody. Nature 491, 406-412 (2012)), was
also tested by ELISA against a panel of HIV-1 antigens (ConsB,
consensus clade B gp140, 426c, clade C gp140, 426c-NLGS, 426c gp140
where the N-linked glycosylation sites were removed, 426c core,
gp140 where the V loops were removed, UG37 gp140, clade A and gp41,
recombinant ecto-domain of gp41, amino acids 541-682 from HxB2
strain, Vybion). None of the tested antigens was recognized by IgG1
LN01 antibody by ELISA (FIG. 10). Conversely, 10E8 antibody reacted
to the recombinant ecto-domain of gp41. These results indicate that
IgG1 LN01 antibody may recognize an epitope in the MPER of gp41
different from 10E8.
[0080] Finally, IgG1 LN01 antibody was tested against a fusion
intermediate gp41 and uncoated plates (PBS), called gp41int (Lai,
R. P. J. et al. A fusion intermediate gp41 immunogen elicits
neutralizing antibodies to HIV-1. J Biol Chem 289, 29912-29926
(2014)). The gp4lint antigen is recognized with high affinity by
MPER antibodies 4E10, 2F5 and 10E8. While 10E8 reacted to gp4lint
by ELISA, IgG1 LN01 antibody did not react (FIG. 11). These results
indicate that IgG1 LN01 antibody recognizes a conserved epitope,
possibly in the MPER region, that is not readily displayed in any
of the antigens tested. We can hypothesize that IgG1 LN01 antibody
recognizes its cognate conformational epitope in the C-teminal
region of the MPER region when displayed in the prefusion native
Env conformation.
Example 5
LN01 Lack of High Affinity Binding to a MPE Peptide
[0081] In order to order to better define the specificity of IgG1
LN01 antibody we tested its binding by ELISA to a 28 amino acids
long peptide that was used to co-crystallize the MPER-specific
antibody 10E8 (Huang et al. Nature 2012). This peptide encompasses
the entire 28-residue gp41 MPER (residues 656-683) (sequence
RRR-NEQELLELDKWASLWNWFDITNWLYIRRRR (SEQ ID NO.:81). While 10E8
reacted to this MPER peptide avidly, IgG1 LN01 antibody reacted to
it very poorly (FIG. 12). These results indicate that IgG1 LN01
antibody recognizes a conserved epitope, possibly in the MPER
region, that is not readily displayed in a linear peptide
encompassing the entire MPER gp41 region.
Example 6
LN01 Variants with Improved Neutralizing Activity
[0082] In order to improve the potency of LN01 antibody we produced
a set of variants where we introduced point mutations in the LN01
VH (25 variants) or in VL (15 variants) (FIG. 13A). These
substitutions were selected based on a predicted surface exposure
by replacing the original residues by W or A. Forty (40) LN01
variants were produced recombinantly by combining the mutated VH or
VL with the parental VL or VH, respectively. These variants were
tested against an initial panel of three HIV-1 strains (CH119,
X1632; BJOX and a control virus SVA-MLV). Several LN01 variants
lost neutralizing activity partially or completely (variants 13,
14, 21, 18, 19, 20, 22, 23, 24, 32 and 33), indicating an important
role for the original residues in antigen recognition (in
particular residues in the FR3 of the VH, in the CDR3 of the VH and
in residues of the CDR1 of the VL). Of note, three variants showed
a more than three-fold (3X) increase in neutralizing potency:
variant 7 (D32W, mutation in the CDR1 of the VH), variant 8 (N33W
in the CDR1 of the VH) and variant 38 (S67W in the FR3 of the VL)
(FIGS. 13B and 13C). Remarkably, LN01 variant 7 showed 39-fold
increase in potency as compared to the parental LN01 antibody.
These results were confirmed when LN01 variants 7, 8 and 38 were
tested in parallel with the parental LN01 antibody against a
multiclade panel of 8 viruses (FIGS. 14A-K). In this second test
the increased potency observed for LN01 variants 7, 8 and 38 was on
average 47, 2.3 and 2.7 fold, respectively.
[0083] Based on these results additional LN01 variants (variants
41, 42, 43, 44, 48 and 50) were synthesized and tested against a
panel of seven HIV-1 strains (FIGS. 15A-B). In variants (v) 41, 42,
43 and 44 the D32 residue of the CDR1 of the VH was mutated to
either F (v41), Y (v42), L (v43) or I (v44). Of interest, none of
these 4 mutations conferred the same increased in potency observed
with the introduction of W in variant 7. In addition, only the
introduction of aromatic resides (i.e., F or Y) improved LN01
activity, with Y (V42) conferring the most significant improvement
of on average 3.7-fold (FIG. 15B). The introduction of hydrophobic
residues in the same position did not confer any benefit in terms
of neutralizing activity. Two variants in which the somatic
mutations in FR1 and FR4 were reverted to the germline
configuration in the presence (variant 48) or absence (variant 50)
of the D32W mutation used in variant 7 were also tested. The
removal of somatic mutations in framework (FR) 1 and FR4 of the VH
did not alter LN01 neutralizing activity significantly. The
introduction of the D32W on the backbone of variant 50 conferred a
more potent neutralizing activity (on average 4.7 fold better than
the parental LN01 antibody). It is worth noting, however, that D32W
in the context of germlined FRs in the VH did not achieve the same
level of potency improvement observed with the same mutation on the
backbone of the fully mutated parental LN01 antibody (i.e., variant
7).
[0084] The combination of the mutations introduced in variants 7
and 8 (D32W and N33W) was also tested in a new variant called 49
that showed an average 81-fold higher potency as compared to the
parental LN01 antibody (FIGS. 16A-B) on a panel of 7 viruses. This
result indicate that LN01 variant 49 is comparable or superior to
the highly potent LN01 variant 7 antibody.
[0085] Finally, we tested another LN01 variant in which the five
CDR1 somatic mutations were reverted back to the germline
configuration. The mutated CDR1 sequence DSVSNDNYY (SEQ ID NO.:82;
including the underlined five CDR1 somatic mutations) was reverted
to GSISSSSYY (SEQ ID NO.:32; germline CDR1) to generate the LN01
variant 82. Surprisingly, LN01 variant 82 showed a potency 2.9-fold
higher than that of the parental LN01 antibody (FIG. 17). This
result indicates that VH CDR1 plays an important role in LN01
neutralizing activity.
[0086] While certain embodiments have been described in terms of
the preferred embodiments, it is understood that variations and
modifications will occur to those skilled in the art. Therefore, it
is intended that the appended claims cover all such equivalent
variations that come within the scope of the following claims.
Sequence CWU 1
1
82110PRTHomo sapiens 1Gly Asp Ser Val Ser Asn Asp Asn Tyr Tyr1 5
1027PRTHomo sapiens 2Ile Tyr Tyr Ser Gly Thr Thr1 5320PRTHomo
sapiens 3Val Arg Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser
Tyr Trp1 5 10 15Tyr Phe Asp Leu 2046PRTHomo sapiens 4Gln Ser Val
Thr Lys Tyr1 559PRTHomo sapiens 5Leu Ile Tyr Gly Thr Tyr Thr Leu
Leu1 569PRTHomo sapiens 6Gln Gln Ala His Ser Thr Pro Trp Thr1
57128PRTHomo sapiens 7Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu
Val Gln Pro Trp Gly1 5 10 15Thr Leu Ser Leu Thr Cys Arg Val Ser Gly
Asp Ser Val Ser Asn Asp 20 25 30Asn Tyr Tyr Trp Ala Trp Ile Arg Gln
Thr Pro Gly Arg Glu Leu Gln 35 40 45Val Ile Gly Thr Ile Tyr Tyr Ser
Gly Thr Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Asn Arg Val Thr Ile
Ser Leu Asp Lys Ser Val Asn Val Val65 70 75 80Ser Leu Arg Leu Gly
Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr 85 90 95Cys Val Arg Met
Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser Tyr 100 105 110Trp Tyr
Phe Asp Leu Trp Gly Arg Gly His Phe Val Ala Val Ser Trp 115 120
1258107PRTHomo sapiens 8Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
Ser Ala Ser Val Gly1 5 10 15Asp Lys Val Thr Ile Thr Cys Arg Ala Ser
Gln Ser Val Thr Lys Tyr 20 25 30Leu Asn Trp Tyr Gln Phe Lys Thr Gly
Gln Ala Pro Arg Ile Leu Ile 35 40 45Tyr Gly Thr Tyr Thr Leu Leu Ser
Gly Val Ser Pro Arg Phe Ser Gly 50 55 60Ala Gly Ser Gly Ser Leu Tyr
Thr Leu Thr Ile Thr Asn Ile Gln Pro65 70 75 80Glu Asp Phe Ala Thr
Tyr Tyr Cys Gln Gln Ala His Ser Thr Pro Trp 85 90 95Thr Phe Gly Gln
Gly Thr His Val Ala Ala Asn 100 1059128PRTHomo sapiens 9Glu Val Gln
Leu Val Glu Ser Gly Pro Gly Leu Val Gln Pro Trp Gly1 5 10 15Thr Leu
Ser Leu Thr Cys Arg Val Ser Gly Asp Ser Val Ser Asn Trp 20 25 30Asn
Tyr Tyr Trp Ala Trp Ile Arg Gln Thr Pro Gly Arg Glu Leu Gln 35 40
45Val Ile Gly Thr Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn Pro Ser
50 55 60Leu Arg Asn Arg Val Thr Ile Ser Leu Asp Lys Ser Val Asn Val
Val65 70 75 80Ser Leu Arg Leu Gly Ser Val Ser Ala Ala Asp Thr Ala
Gln Tyr Tyr 85 90 95Cys Val Arg Met Pro Ser His Gly Phe Trp Ser Thr
Ser Phe Ser Tyr 100 105 110Trp Tyr Phe Asp Leu Trp Gly Arg Gly His
Phe Val Ala Val Ser Trp 115 120 12510107PRTHomo sapiens 10Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp
Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Thr Lys Tyr 20 25
30Leu Asn Trp Tyr Gln Phe Lys Thr Gly Gln Ala Pro Arg Ile Leu Ile
35 40 45Tyr Gly Thr Tyr Thr Leu Leu Ser Gly Val Ser Pro Arg Phe Ser
Gly 50 55 60Ala Gly Ser Gly Ser Leu Tyr Thr Leu Thr Ile Thr Asn Ile
Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala His
Ser Thr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr His Val Ala Ala Asn
100 10511128PRTHomo sapiens 11Glu Val Gln Leu Val Glu Ser Gly Pro
Gly Leu Val Gln Pro Trp Gly1 5 10 15Thr Leu Ser Leu Thr Cys Arg Val
Ser Gly Asp Ser Val Ser Asn Asp 20 25 30Trp Tyr Tyr Trp Ala Trp Ile
Arg Gln Thr Pro Gly Arg Glu Leu Gln 35 40 45Val Ile Gly Thr Ile Tyr
Tyr Ser Gly Thr Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Asn Arg Val
Thr Ile Ser Leu Asp Lys Ser Val Asn Val Val65 70 75 80Ser Leu Arg
Leu Gly Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr 85 90 95Cys Val
Arg Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser Tyr 100 105
110Trp Tyr Phe Asp Leu Trp Gly Arg Gly His Phe Val Ala Val Ser Trp
115 120 12512107PRTHomo sapiens 12Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Lys Val Thr Ile Thr Cys
Arg Ala Ser Gln Ser Val Thr Lys Tyr 20 25 30Leu Asn Trp Tyr Gln Phe
Lys Thr Gly Gln Ala Pro Arg Ile Leu Ile 35 40 45Tyr Gly Thr Tyr Thr
Leu Leu Ser Gly Val Ser Pro Arg Phe Ser Gly 50 55 60Ala Gly Ser Gly
Ser Leu Tyr Thr Leu Thr Ile Thr Asn Ile Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Thr Pro Trp 85 90 95Thr
Phe Gly Gln Gly Thr His Val Ala Ala Asn 100 10513128PRTHomo sapiens
13Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Gln Pro Trp Gly1
5 10 15Thr Leu Ser Leu Thr Cys Arg Val Ser Gly Asp Ser Val Ser Asn
Asp 20 25 30Asn Tyr Tyr Trp Ala Trp Ile Arg Gln Thr Pro Gly Arg Glu
Leu Gln 35 40 45Val Ile Gly Thr Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr
Asn Pro Ser 50 55 60Leu Arg Asn Arg Val Thr Ile Ser Leu Asp Lys Ser
Val Asn Val Val65 70 75 80Ser Leu Arg Leu Gly Ser Val Ser Ala Ala
Asp Thr Ala Gln Tyr Tyr 85 90 95Cys Val Arg Met Pro Ser His Gly Phe
Trp Ser Thr Ser Phe Ser Tyr 100 105 110Trp Tyr Phe Asp Leu Trp Gly
Arg Gly His Phe Val Ala Val Ser Trp 115 120 12514107PRTHomo sapiens
14Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Thr Lys
Tyr 20 25 30Leu Asn Trp Tyr Gln Phe Lys Thr Gly Gln Ala Pro Arg Ile
Leu Ile 35 40 45Tyr Gly Thr Tyr Thr Leu Leu Ser Gly Val Ser Pro Arg
Phe Ser Gly 50 55 60Ala Gly Trp Gly Ser Leu Tyr Thr Leu Thr Ile Thr
Asn Ile Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala His Ser Thr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr His Val Ala
Ala Asn 100 10515128PRTHomo sapiens 15Glu Val Gln Leu Val Glu Ser
Gly Pro Gly Leu Val Gln Pro Trp Gly1 5 10 15Thr Leu Ser Leu Thr Cys
Arg Val Ser Gly Asp Ser Val Ser Asn Phe 20 25 30Asn Tyr Tyr Trp Ala
Trp Ile Arg Gln Thr Pro Gly Arg Glu Leu Gln 35 40 45Val Ile Gly Thr
Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Asn
Arg Val Thr Ile Ser Leu Asp Lys Ser Val Asn Val Val65 70 75 80Ser
Leu Arg Leu Gly Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr 85 90
95Cys Val Arg Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser Tyr
100 105 110Trp Tyr Phe Asp Leu Trp Gly Arg Gly His Phe Val Ala Val
Ser Trp 115 120 12516107PRTHomo sapiens 16Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Lys Val Thr Ile
Thr Cys Arg Ala Ser Gln Ser Val Thr Lys Tyr 20 25 30Leu Asn Trp Tyr
Gln Phe Lys Thr Gly Gln Ala Pro Arg Ile Leu Ile 35 40 45Tyr Gly Thr
Tyr Thr Leu Leu Ser Gly Val Ser Pro Arg Phe Ser Gly 50 55 60Ala Gly
Ser Gly Ser Leu Tyr Thr Leu Thr Ile Thr Asn Ile Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Thr Pro Trp
85 90 95Thr Phe Gly Gln Gly Thr His Val Ala Ala Asn 100
10517128PRTHomo sapiens 17Glu Val Gln Leu Val Glu Ser Gly Pro Gly
Leu Val Gln Pro Trp Gly1 5 10 15Thr Leu Ser Leu Thr Cys Arg Val Ser
Gly Asp Ser Val Ser Asn Tyr 20 25 30Asn Tyr Tyr Trp Ala Trp Ile Arg
Gln Thr Pro Gly Arg Glu Leu Gln 35 40 45Val Ile Gly Thr Ile Tyr Tyr
Ser Gly Thr Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Asn Arg Val Thr
Ile Ser Leu Asp Lys Ser Val Asn Val Val65 70 75 80Ser Leu Arg Leu
Gly Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr 85 90 95Cys Val Arg
Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser Tyr 100 105 110Trp
Tyr Phe Asp Leu Trp Gly Arg Gly His Phe Val Ala Val Ser Trp 115 120
12518107PRTHomo sapiens 18Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Lys Val Thr Ile Thr Cys Arg Ala
Ser Gln Ser Val Thr Lys Tyr 20 25 30Leu Asn Trp Tyr Gln Phe Lys Thr
Gly Gln Ala Pro Arg Ile Leu Ile 35 40 45Tyr Gly Thr Tyr Thr Leu Leu
Ser Gly Val Ser Pro Arg Phe Ser Gly 50 55 60Ala Gly Ser Gly Ser Leu
Tyr Thr Leu Thr Ile Thr Asn Ile Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala His Ser Thr Pro Trp 85 90 95Thr Phe Gly
Gln Gly Thr His Val Ala Ala Asn 100 10519128PRTHomo sapiens 19Gln
Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10
15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Val Ser Asn Trp
20 25 30Asn Tyr Tyr Trp Ala Trp Ile Arg Gln Thr Pro Gly Arg Glu Leu
Gln 35 40 45Val Ile Gly Thr Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn
Pro Ser 50 55 60Leu Arg Asn Arg Val Thr Ile Ser Leu Asp Lys Ser Val
Asn Val Val65 70 75 80Ser Leu Arg Leu Gly Ser Val Ser Ala Ala Asp
Thr Ala Gln Tyr Tyr 85 90 95Cys Val Arg Met Pro Ser His Gly Phe Trp
Ser Thr Ser Phe Ser Tyr 100 105 110Trp Tyr Phe Asp Leu Trp Gly Arg
Gly Thr Leu Val Thr Val Ser Ser 115 120 12520107PRTHomo sapiens
20Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Thr Lys
Tyr 20 25 30Leu Asn Trp Tyr Gln Phe Lys Thr Gly Gln Ala Pro Arg Ile
Leu Ile 35 40 45Tyr Gly Thr Tyr Thr Leu Leu Ser Gly Val Ser Pro Arg
Phe Ser Gly 50 55 60Ala Gly Ser Gly Ser Leu Tyr Thr Leu Thr Ile Thr
Asn Ile Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala His Ser Thr Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr His Val Ala
Ala Asn 100 10521128PRTHomo sapiens 21Glu Val Gln Leu Val Glu Ser
Gly Pro Gly Leu Val Gln Pro Trp Gly1 5 10 15Thr Leu Ser Leu Thr Cys
Arg Val Ser Gly Asp Ser Val Ser Asn Trp 20 25 30Trp Tyr Tyr Trp Ala
Trp Ile Arg Gln Thr Pro Gly Arg Glu Leu Gln 35 40 45Val Ile Gly Thr
Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Asn
Arg Val Thr Ile Ser Leu Asp Lys Ser Val Asn Val Val65 70 75 80Ser
Leu Arg Leu Gly Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr 85 90
95Cys Val Arg Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser Tyr
100 105 110Trp Tyr Phe Asp Leu Trp Gly Arg Gly His Phe Val Ala Val
Ser Trp 115 120 12522107PRTHomo sapiens 22Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Lys Val Thr Ile
Thr Cys Arg Ala Ser Gln Ser Val Thr Lys Tyr 20 25 30Leu Asn Trp Tyr
Gln Phe Lys Thr Gly Gln Ala Pro Arg Ile Leu Ile 35 40 45Tyr Gly Thr
Tyr Thr Leu Leu Ser Gly Val Ser Pro Arg Phe Ser Gly 50 55 60Ala Gly
Ser Gly Ser Leu Tyr Thr Leu Thr Ile Thr Asn Ile Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Thr Pro Trp
85 90 95Thr Phe Gly Gln Gly Thr His Val Ala Ala Asn 100
10523128PRTHomo sapiens 23Gln Val Gln Leu Glu Glu Ser Gly Pro Gly
Leu Val Gln Pro Trp Gly1 5 10 15Thr Leu Ser Leu Thr Cys Arg Val Ser
Gly Gly Ser Ile Ser Ser Ser 20 25 30Ser Tyr Tyr Trp Ala Trp Ile Arg
Gln Thr Pro Gly Arg Glu Leu Gln 35 40 45Val Ile Gly Thr Ile Tyr Tyr
Ser Gly Thr Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Asn Arg Val Thr
Ile Ser Leu Asp Lys Ser Val Asn Val Val65 70 75 80Ser Leu Arg Leu
Gly Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr 85 90 95Cys Val Arg
Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser Tyr 100 105 110Trp
Tyr Phe Asp Leu Trp Gly Arg Gly His Phe Val Ala Val Ser Trp 115 120
12524107PRTHomo sapiens 24Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Lys Val Thr Ile Thr Cys Arg Ala
Ser Gln Ser Val Thr Lys Tyr 20 25 30Leu Asn Trp Tyr Gln Phe Lys Thr
Gly Gln Ala Pro Arg Ile Leu Ile 35 40 45Tyr Gly Thr Tyr Thr Leu Leu
Ser Gly Val Ser Pro Arg Phe Ser Gly 50 55 60Ala Gly Ser Gly Ser Leu
Tyr Thr Leu Thr Ile Thr Asn Ile Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala His Ser Thr Pro Trp 85 90 95Thr Phe Gly
Gln Gly Thr His Val Ala Ala Asn 100 1052510PRTHomo sapiens 25Gly
Asp Ser Val Ser Asn Trp Asn Tyr Tyr1 5 102610PRTHomo sapiens 26Gly
Asp Ser Val Ser Asn Asp Trp Tyr Tyr1 5 102710PRTHomo sapiens 27Gly
Asp Ser Val Ser Asn Phe Asn Tyr Tyr1 5 102810PRTHomo sapiens 28Gly
Asp Ser Val Ser Asn Tyr Asn Tyr Tyr1 5 102910PRTHomo sapiens 29Gly
Asp Ser Val Ser Asn Leu Asn Tyr Tyr1 5 103010PRTHomo sapiens 30Gly
Asp Ser Val Ser Asn Ile Asn Tyr Tyr1 5 103110PRTHomo sapiens 31Gly
Asp Ser Val Ser Asn Trp Trp Tyr Tyr1 5 10329PRTHomo sapiens 32Gly
Ser Ile Ser Ser Ser Ser Tyr Tyr1 53330DNAHomo sapiens 33ggtgactcag
tcagtaatga taattattat 303421DNAHomo sapiens 34atctattaca gcggcacaac
c 213560DNAHomo sapiens 35gttcgcatgc ccagtcacgg attttggagt
acttctttct cttactggta tttcgatctc 603618DNAHomo sapiens 36cagagtgtca
ccaaatat 183727DNAHomo sapiens 37ctcatctatg ggacttatac tttactc
273827DNAHomo sapiens 38caacaggctc acagtactcc ctggacc
2739384DNAHomo sapiens 39gaggtgcagc tggtggagtc gggcccagga
ctggtgcagc cctgggggac cctgtccctc 60acctgtcgtg tctctggtga ctcagtcagt
aatgataatt attattgggc ctggattcgc 120cagacccccg ggagggaact
gcaggtcatc ggaactatct attacagcgg cacaacctac 180tacaatccgt
cgctcaggaa tcgagtcacg atctcattgg acaagtccgt caatgtggtc
240tccctgagat tggggtctgt gagtgccgcg gacacggccc aatattattg
cgttcgcatg 300cccagtcacg gattttggag tacttctttc tcttactggt
atttcgatct ctggggccgt 360ggtcatttcg tcgctgtctc ctgg
38440321DNAHomo sapiens 40gacatccaga tgacccagtc tccgtcctcc
ctgtctgcct ctgttggaga caaagtcacc 60atcacctgcc gggccagtca gagtgtcacc
aaatatttaa attggtatca gtttaagacc 120ggccaagccc caagaatcct
catctatggg acttatactt tactcagtgg cgtctcgcct 180cggttcagtg
gcgccggatc tggttcactc tacactctga ccatcaccaa tatacagcct
240gaagacttcg ccacctatta ttgtcaacag gctcacagta ctccctggac
cttcggccaa 300ggaacccacg tggcggccaa c 32141384DNAHomo sapiens
41gaagtgcagc tggtggaatc tggccctggc ctggtgcagc cttggggcac actgagcctg
60acctgtagag tgtccggcga cagcgtgtcc aactggaact actactgggc ctggatccgg
120cagacccccg gcagagaact gcaagtgatc ggcaccatct actacagcgg
cacaacctac 180tacaacccca gcctgcggaa cagagtgacc atcagcctgg
acaagagcgt gaacgtggtg 240tccctgagac tgggctctgt gtctgccgcc
gataccgccc agtactactg cgtgcggatg 300cccagccacg gcttctggtc
taccagcttc agctactggt acttcgacct gtggggcaga 360ggccacttcg
tggccgtgtc ttgg 38442321DNAHomo sapiens 42gacatccaga tgacccagtc
tccgtcctcc ctgtctgcct ctgttggaga caaagtcacc 60atcacctgcc gggccagtca
gagtgtcacc aaatatttaa attggtatca gtttaagacc 120ggccaagccc
caagaatcct catctatggg acttatactt tactcagtgg cgtctcgcct
180cggttcagtg gcgccggatc tggttcactc tacactctga ccatcaccaa
tatacagcct 240gaagacttcg ccacctatta ttgtcaacag gctcacagta
ctccctggac cttcggccaa 300ggaacccacg tggcggccaa c 32143384DNAHomo
sapiens 43gaagtgcagc tggtggaatc tggccctggc ctggtgcagc cttggggcac
actgagcctg 60acctgtagag tgtccggcga cagcgtgtcc aacgactggt actactgggc
ctggatccgg 120cagacccccg gcagagaact gcaagtgatc ggcaccatct
actacagcgg cacaacctac 180tacaacccca gcctgcggaa cagagtgacc
atcagcctgg acaagagcgt gaacgtggtg 240tccctgagac tgggctctgt
gtctgccgcc gataccgccc agtactactg cgtgcggatg 300cccagccacg
gcttctggtc taccagcttc agctactggt acttcgacct gtggggcaga
360ggccacttcg tggccgtgtc ttgg 38444321DNAHomo sapiens 44gacatccaga
tgacccagag ccccagcagc ctgtctgcca gcgtgggcga caaagtgacc 60atcacctgtc
gggccagcca gagcgtgacc aagtacctga actggtatca gtttaagacc
120ggccaggccc ccagaatcct gatctacggc acctacaccc tgctgagcgg
cgtgtcccct 180agattctctg gcgccggaag cggcagcctg tacaccctga
caatcaccaa catccagccc 240gaggacttcg ccacctacta ctgccagcag
gcccacagca ccccttggac atttggccag 300ggaacacacg tggccgccaa c
32145383DNAHomo sapiens 45aagtgcagct ggtggaatct ggccctggcc
tggtgcagcc ttggggcaca ctgagcctga 60cctgtagagt gtccggcgac agcgtgtcca
acgacaacta ctactgggcc tggatccggc 120agacccccgg cagagaactg
caagtgatcg gcaccatcta ctacagcggc acaacctact 180acaaccccag
cctgcggaac agagtgacca tcagcctgga caagagcgtg aacgtggtgt
240ccctgagact gggctctgtg tctgccgccg ataccgccca gtactactgc
gtgcggatgc 300ccagccacgg cttctggtct accagcttca gctactggta
cttcgacctg tggggcagag 360gccacttcgt ggccgtgtct tgg 38346320DNAHomo
sapiens 46acatccagat gacccagagc cccagcagcc tgtctgccag cgtgggcgac
aaagtgacca 60tcacctgtcg ggccagccag agcgtgacca agtacctgaa ctggtatcag
tttaagaccg 120gccaggcccc cagaatcctg atctacggca cctacaccct
gctgagcggc gtgtccccta 180gattctctgg cgccggatgg ggcagcctgt
acaccctgac aatcaccaac atccagcccg 240aggacttcgc cacctactac
tgccagcagg cccacagcac cccttggaca tttggccagg 300gaacacacgt
ggccgccaac 32047384DNAHomo sapiens 47gaggtgcagc tggtggaatc
tggacctgga ctggtgcagc cttggggcac tctgtctctg 60acatgccggg tgagcgggga
cagcgtctcc aactttaatt actattgggc ttggatcagg 120cagacaccag
ggcgcgagct gcaggtcatc gggactatct actattccgg aaccacatac
180tataacccct ctctgcggaa tagagtgacc atttctctgg acaagagtgt
caacgtggtc 240agtctgcgac tgggatctgt gagtgccgct gataccgcac
agtactattg cgtgcggatg 300ccctctcacg gcttctggtc aacaagcttt
tcctactggt atttcgatct gtggggacgg 360ggccatttcg tggccgtctc ctgg
38448321DNAHomo sapiens 48gacatccaga tgacccagtc tccgtcctcc
ctgtctgcct ctgttggaga caaagtcacc 60atcacctgcc gggccagtca gagtgtcacc
aaatatttaa attggtatca gtttaagacc 120ggccaagccc caagaatcct
catctatggg acttatactt tactcagtgg cgtctcgcct 180cggttcagtg
gcgccggatc tggttcactc tacactctga ccatcaccaa tatacagcct
240gaagacttcg ccacctatta ttgtcaacag gctcacagta ctccctggac
cttcggccaa 300ggaacccacg tggcggccaa c 32149384DNAHomo sapiens
49gaggtgcagc tggtggaatc tggacctgga ctggtgcagc cttggggcac tctgtctctg
60acatgccggg tgagcgggga cagcgtctcc aactacaatt actattgggc ttggatcagg
120cagacaccag ggcgcgagct gcaggtcatc gggactatct actattccgg
aaccacatac 180tataacccct ctctgcggaa tagagtgacc atttctctgg
acaagagtgt caacgtggtc 240agtctgcgac tgggatctgt gagtgccgct
gataccgcac agtactattg cgtgcggatg 300ccctctcacg gcttctggtc
aacaagcttt tcctactggt atttcgatct gtggggacgg 360ggccattttg
tggccgtctc ctgg 38450321DNAHomo sapiens 50gacatccaga tgacccagtc
tccgtcctcc ctgtctgcct ctgttggaga caaagtcacc 60atcacctgcc gggccagtca
gagtgtcacc aaatatttaa attggtatca gtttaagacc 120ggccaagccc
caagaatcct catctatggg acttatactt tactcagtgg cgtctcgcct
180cggttcagtg gcgccggatc tggttcactc tacactctga ccatcaccaa
tatacagcct 240gaagacttcg ccacctatta ttgtcaacag gctcacagta
ctccctggac cttcggccaa 300ggaacccacg tggcggccaa c 32151384DNAHomo
sapiens 51cagctgcagc tgcaggagag tggacctgga ctggtgaagc cttcagaaac
actgagcctg 60acttgcaccg tgtccggcga ctctgtcagt aactggaatt actattgggc
atggattaga 120cagacaccag gaagagagct gcaggtcatc gggacaatct
actatagtgg aaccacatac 180tataacccct cactgcggaa tagagtgacc
atttccctgg acaaatctgt caacgtggtc 240tctctgcgac tgggctcagt
gagcgccgct gatactgccc agtactattg cgtgcggatg 300cccagccacg
gcttctggtc cacctctttt agttactggt atttcgatct gtggggacgg
360ggcacactgg tgactgtcag ctcc 38452321DNAHomo sapiens 52gacatccaga
tgacccagtc tccgtcctcc ctgtctgcct ctgttggaga caaagtcacc 60atcacctgcc
gggccagtca gagtgtcacc aaatatttaa attggtatca gtttaagacc
120ggccaagccc caagaatcct catctatggg acttatactt tactcagtgg
cgtctcgcct 180cggttcagtg gcgccggatc tggttcactc tacactctga
ccatcaccaa tatacagcct 240gaagacttcg ccacctatta ttgtcaacag
gctcacagta ctccctggac cttcggccaa 300ggaacccacg tggcggccaa c
32153384DNAHomo sapiens 53gaggtgcagc tggtggaatc tggacctgga
ctggtgcagc cttggggcac tctgtctctg 60acatgccggg tgagcgggga cagcgtctcc
aactggtggt actattgggc ttggatcagg 120cagacaccag ggcgcgagct
gcaggtcatc gggactatct actattccgg aaccacatac 180tataacccct
ctctgcggaa tagagtgacc atttctctgg acaagagtgt caatgtggtc
240agtctgcgac tgggatctgt gagtgccgct gataccgcac agtactattg
cgtgcggatg 300ccctctcacg gcttctggtc aacaagcttt tcctactggt
atttcgatct gtggggacgg 360ggccattttg tggccgtctc ctgg 38454321DNAHomo
sapiens 54gacatccaga tgacccagtc tccgtcctcc ctgtctgcct ctgttggaga
caaagtcacc 60atcacctgcc gggccagtca gagtgtcacc aaatatttaa attggtatca
gtttaagacc 120ggccaagccc caagaatcct catctatggg acttatactt
tactcagtgg cgtctcgcct 180cggttcagtg gcgccggatc tggttcactc
tacactctga ccatcaccaa tatacagcct 240gaagacttcg ccacctatta
ttgtcaacag gctcacagta ctccctggac cttcggccaa 300ggaacccacg
tggcggccaa c 32155384DNAHomo sapiens 55caggtgcagc tggaggaatc
tggacctgga ctggtccagc cttgggggac tctgagcctg 60acctgccggg tgtcaggcgg
gagcatcagc tcctctagtt actattgggc ttggattagg 120cagacaccag
gccgcgagct gcaggtcatc ggcactatct actatagtgg gaccacatac
180tataacccct cactgcggaa tagagtgacc atctccctgg acaagtctgt
caacgtggtc 240tctctgcgac tgggatcagt gagcgccgct gataccgcac
agtactattg cgtgcggatg 300cccagccacg gcttctggtc cacatctttt
agttactggt atttcgacct gtgggggcgg 360ggacattttg tggccgtcag ttgg
38456321DNAHomo sapiens 56gacatccaga tgacccagtc tccgtcctcc
ctgtctgcct ctgttggaga caaagtcacc 60atcacctgcc gggccagtca gagtgtcacc
aaatatttaa attggtatca gtttaagacc 120ggccaagccc caagaatcct
catctatggg acttatactt tactcagtgg cgtctcgcct 180cggttcagtg
gcgccggatc tggttcactc tacactctga ccatcaccaa tatacagcct
240gaagacttcg ccacctatta ttgtcaacag gctcacagta ctccctggac
cttcggccaa 300ggaacccacg tggcggccaa c 3215730DNAHomo sapiens
57ggcgacagcg tgtccaactg gaactactac 305830DNAHomo sapiens
58ggcgacagcg tgtccaacga ctggtactac 305930DNAHomo sapiens
59ggggacagcg tctccaactt taattactat 306030DNAHomo sapiens
60ggggacagcg tctccaacta caattactat 306130DNAHomo sapiens
61ggggacagcg tctccaactt aaattactat 306230DNAHomo sapiens
62ggggacagcg tctccaacat taattactat 306330DNAHomo sapiens
63ggggacagcg tctccaactg gtggtactat 306427DNAHomo sapiens
64gggagcatca gctcctctag ttactat 27659PRTHomo sapiens 65Leu Ala Ser
Trp Val Lys Tyr Ile Gln1 5669PRTHomo sapiens 66Ile Thr Lys Trp Leu
Trp Tyr Ile Lys1 5679PRTHomo sapiens 67Ile Thr Ser Trp Ile Lys Tyr
Ile Gln1 568856PRTHomo sapiens 68Met Arg Val Lys Glu Lys Tyr Gln
His Leu Trp Arg Trp Gly Trp Arg1 5 10 15Trp Gly Thr Met Leu Leu Gly
Met Leu Met Ile Cys Ser Ala Thr Glu 20 25 30Lys Leu Trp Val Thr Val
Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala 35 40 45Thr Thr Thr Leu Phe
Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu 50 55 60Val His Asn Val
Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn65 70 75 80Pro Gln
Glu Val Val Leu Val Asn Val Thr Glu Asn Phe Asn Met Trp 85 90 95Lys
Asn Asp Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp 100 105
110Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Ser
115 120 125Leu Lys Cys Thr Asp Leu Lys Asn Asp Thr Asn Thr Asn Ser
Ser Ser 130 135 140Gly Arg Met Ile Met Glu Lys Gly Glu Ile Lys Asn
Cys Ser Phe Asn145 150 155 160Ile Ser Thr Ser Ile Arg Gly Lys Val
Gln Lys Glu Tyr Ala Phe Phe 165 170 175Tyr Lys Leu Asp Ile Ile Pro
Ile Asp Asn Asp Thr Thr Ser Tyr Lys 180 185 190Leu Thr Ser Cys Asn
Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val 195 200 205Ser Phe Glu
Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala 210 215 220Ile
Leu Lys Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr225 230
235 240Asn Val Ser Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val
Ser 245 250 255Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu
Val Val Ile 260 265 270Arg Ser Val Asn Phe Thr Asp Asn Ala Lys Thr
Ile Ile Val Gln Leu 275 280 285Asn Thr Ser Val Glu Ile Asn Cys Thr
Arg Pro Asn Asn Asn Thr Arg 290 295 300Lys Arg Ile Arg Ile Gln Arg
Gly Pro Gly Arg Ala Phe Val Thr Ile305 310 315 320Gly Lys Ile Gly
Asn Met Arg Gln Ala His Cys Asn Ile Ser Arg Ala 325 330 335Lys Trp
Asn Asn Thr Leu Lys Gln Ile Ala Ser Lys Leu Arg Glu Gln 340 345
350Phe Gly Asn Asn Lys Thr Ile Ile Phe Lys Gln Ser Ser Gly Gly Asp
355 360 365Pro Glu Ile Val Thr His Ser Phe Asn Cys Gly Gly Glu Phe
Phe Tyr 370 375 380Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Trp Phe
Asn Ser Thr Trp385 390 395 400Ser Thr Glu Gly Ser Asn Asn Thr Glu
Gly Ser Asp Thr Ile Thr Leu 405 410 415Pro Cys Arg Ile Lys Gln Ile
Ile Asn Met Trp Gln Lys Val Gly Lys 420 425 430Ala Met Tyr Ala Pro
Pro Ile Ser Gly Gln Ile Arg Cys Ser Ser Asn 435 440 445Ile Thr Gly
Leu Leu Leu Thr Arg Asp Gly Gly Asn Ser Asn Asn Glu 450 455 460Ser
Glu Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg465 470
475 480Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly
Val 485 490 495Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu
Lys Arg Ala 500 505 510Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu
Gly Ala Ala Gly Ser 515 520 525Thr Met Gly Ala Ala Ser Met Thr Leu
Thr Val Gln Ala Arg Gln Leu 530 535 540Leu Ser Gly Ile Val Gln Gln
Gln Asn Asn Leu Leu Arg Ala Ile Glu545 550 555 560Ala Gln Gln His
Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu 565 570 575Gln Ala
Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu 580 585
590Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val
595 600 605Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Glu Gln Ile
Trp Asn 610 615 620His Thr Thr Trp Met Glu Trp Asp Arg Glu Ile Asn
Asn Tyr Thr Ser625 630 635 640Leu Ile His Ser Leu Ile Glu Glu Ser
Gln Asn Gln Gln Glu Lys Asn 645 650 655Glu Gln Glu Leu Leu Glu Leu
Asp Lys Trp Ala Ser Leu Trp Asn Trp 660 665 670Phe Asn Ile Thr Asn
Trp Leu Trp Tyr Ile Lys Leu Phe Ile Met Ile 675 680 685Val Gly Gly
Leu Val Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile 690 695 700Val
Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr His705 710
715 720Leu Pro Thr Pro Arg Gly Pro Asp Arg Pro Glu Gly Ile Glu Glu
Glu 725 730 735Gly Gly Glu Arg Asp Arg Asp Arg Ser Ile Arg Leu Val
Asn Gly Ser 740 745 750Leu Ala Leu Ile Trp Asp Asp Leu Arg Ser Leu
Cys Leu Phe Ser Tyr 755 760 765His Arg Leu Arg Asp Leu Leu Leu Ile
Val Thr Arg Ile Val Glu Leu 770 775 780Leu Gly Arg Arg Gly Trp Glu
Ala Leu Lys Tyr Trp Trp Asn Leu Leu785 790 795 800Gln Tyr Trp Ser
Gln Glu Leu Lys Asn Ser Ala Val Ser Leu Leu Asn 805 810 815Ala Thr
Ala Ile Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val 820 825
830Val Gln Gly Ala Cys Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg
835 840 845Gln Gly Leu Glu Arg Ile Leu Leu 850 85569200PRTHomo
sapiens 69Ala Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala
Ala Gly1 5 10 15Ser Thr Met Gly Ala Ala Ser Met Thr Leu Thr Val Gln
Ala Arg Gln 20 25 30Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu
Leu Arg Ala Ile 35 40 45Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val
Trp Gly Ile Lys Gln 50 55 60Leu Gln Ala Arg Ile Leu Ala Val Glu Arg
Tyr Leu Lys Asp Gln Gln65 70 75 80Leu Leu Gly Ile Trp Gly Cys Ser
Gly Lys Leu Ile Cys Thr Thr Ala 85 90 95Val Pro Trp Asn Ala Ser Trp
Ser Asn Lys Ser Leu Glu Gln Ile Trp 100 105 110Asn Asn Met Thr Trp
Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr 115 120 125Ser Leu Ile
His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys 130 135 140Asn
Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn145 150
155 160Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Lys Leu Phe Ile
Met 165 170 175Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala
Val Leu Ser 180 185 190Ile Val Asn Arg Val Arg Gln Gly 195
2007065PRTHomo sapiens 70Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn
Pro Ser Leu Arg Asn Arg1 5 10 15Val Thr Ile Ser Leu Trp Lys Ser Val
Asn Val Val Ser Leu Arg Leu 20 25 30Gly Ser Val Ser Ala Ala Asp Thr
Ala Gln Tyr Tyr Cys Val Arg Met 35 40 45Pro Ser His Gly Phe Trp Ser
Thr Ser Phe Ser Tyr Trp Tyr Phe Asp 50 55 60Leu657165PRTHomo
sapiens 71Ile Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn Pro Ser Leu Arg
Asn Arg1 5 10 15Val Thr Ile Ser Leu Asp Trp Ser Val Asn Val Val Ser
Leu Arg Leu 20 25 30Gly Ser Val Ser Ala Ala Asp Thr Ala Gln Tyr Tyr
Cys Val Arg Met 35 40 45Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser
Tyr Trp Tyr Phe Asp 50 55 60Leu657220PRTHomo
sapiens 72Val Arg Met Pro Ser His Gly Ala Trp Ser Thr Ser Phe Ser
Tyr Trp1 5 10 15Tyr Phe Asp Leu 207320PRTHomo sapiens 73Val Arg Met
Pro Ser His Gly Phe Ala Ser Thr Ser Phe Ser Tyr Trp1 5 10 15Tyr Phe
Asp Leu 207420PRTHomo sapiens 74Val Arg Met Pro Ser His Gly Phe Trp
Trp Thr Ser Phe Ser Tyr Trp1 5 10 15Tyr Phe Asp Leu 207520PRTHomo
sapiens 75Val Arg Met Pro Ser His Gly Phe Trp Ser Trp Ser Phe Ser
Tyr Trp1 5 10 15Tyr Phe Asp Leu 207620PRTHomo sapiens 76Val Arg Met
Pro Ser His Gly Phe Trp Ser Thr Trp Phe Ser Tyr Trp1 5 10 15Tyr Phe
Asp Leu 207720PRTHomo sapiens 77Val Arg Met Pro Ser His Gly Phe Trp
Ser Thr Ser Phe Trp Tyr Trp1 5 10 15Tyr Phe Asp Leu 207820PRTHomo
sapiens 78Val Arg Met Pro Ser His Gly Phe Trp Ser Thr Ser Phe Ser
Trp Trp1 5 10 15Tyr Phe Asp Leu 20796PRTHomo sapiens 79Gln Ser Val
Thr Trp Tyr1 5806PRTHomo sapiens 80Gln Ser Val Thr Lys Trp1
58134PRTHomo sapiens 81Arg Arg Arg Asn Glu Gln Glu Leu Leu Glu Leu
Asp Lys Trp Ala Ser1 5 10 15Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp
Leu Trp Tyr Ile Arg Arg 20 25 30Arg Arg829PRTHomo sapiens 82Asp Ser
Val Ser Asn Asp Asn Tyr Tyr1 5
* * * * *